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Abstract

Colloidal inorganic nanoparticles (NPs) have been attracting considerable interest in
biomedicine, from drug and gene delivery to imaging, sensing and diagnostics. It is
essential to modify the surface of nanoparticles to have enhanced biocompatibility and
functionality for the in vitro and in vivo applications, especially in delivering locally and
recognizing biomolecules. Herein, the goal of this research work is to develop advanced
NPs with well-tailored surface functionalities and/or bio-functionality for the applications
in cell tracking and analytes detection.
In the first project, quantum dots incorporating with gelatin nanoparticles (QDs-GNPs)
have been developed for bioimaging applications. Two different approaches have been
developed, i.e. directly encapsulating QDs with gelatin polymer (QDs-GNP1) and layerby-layer (LBL) adsorption of QDs approach (QDs-GNP2), respectively. The special
hybrid structures of two QDs-GNPs nanosystems were investigated by transmittance
electron microscopy, scanning electron microscopy, X-ray energy dispersion, Fourier
Transform Infrared spectroscopy, fluorometer, and confocal fluorescent microscopy. Both
nanosystems exhibit high intensive luminescence and good biocompatibility. Compared
to free QDs, QDs-GNP2 shows improved quantum yield and longer lifetime, due to
multiple layers of polyelectrolytes protection. Furthermore, QDs-GNP2 demonstrates the
proton-resistant properties in term of PL intensity and lifetime. The bright and stable
photoluminescence (PL) allows the QD-GNP2 for labeling living 3T3 cells in vitro,
which may indicate the QDs-GNP2 are able to be a suitable candidate for bio-imaging
application.
In the second project, fluorescent magnetic nanoparticles (FMNPs) were bioconjugated
with gentamicin (Gm) for rapid capture, detection and decontamination of bacteria. The
Gm-FMNPs consist of a fluorescent silica shell and an iron oxide magnetic core. Initially,
we prepared the core-shell NPs through a one-pot reaction. The antibacterial efficiency is
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found 20 % higher than that of the free antibiotic. We further improved NPs stability and
capture efficiency by a two-step thermal decomposition method to produce the
fluorescent magnetic core-shell nanoparticles. It is noted that one mg of gentamicin
conjugated FMNPs are able to capture both gram-negative bacteria Escherichia coli and
gram-positive bacteria Staphylococcus aureus as low as 1x104 colony-forming unit/mL
(cfu/mL) in less than one minute. It is expected that the Gm-FMNPs could be a promising
multifunctional platform for disease control in clinic and wastewater treatment.
In addition, a nanosensor for detecting human thrombin has been designed and
developed. A recombinant luciferase was covalently conjugated to gold nanoparticles (Au
NPs) through 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) mediated reaction.
The conjugation enables Au NPs to quench the bioluminescence produced by luciferase.
Recovery of bioluminescence has been studied as a function of the concentration of
thrombin. The results indicate that the designed nanosensor can efficiently detect a
protease thrombin in both buffer and human urine spiked buffer. A linear assay response
is found between 300 ng/mL to 300 µg/mL, with limit of detection (LOD) of 3 ng/mL in
both buffer and human urine spiked samples. The assay time can be less than 15 min. The
nanosensor can thus be a promising tool for clinical diagnostic of thrombin related
diseases.
In summary, different strategies have been explored to engineer the surface of hybrid NPs
with good water stability, biocompatibility and enhanced chemical and physical
properties. The thesis addresses that engineered hybrid NPs in biomedicine and how the
biofunctionalized NPs can find applications in imaging and diagnostics indistinctly.

Keywords:

Fluorescent, magnetic, nanoparticles, gold nanoparticles, quantum dots,

surface functionalization, bioconjugation, biosensing, bioimaging.
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CHAPTER 1
GENERAL INTRODUCTION AND MOTIVATION

1

1.1 Overview of nanoparticles in biomedical applications
The term “nanotechnology” is defined as the creation and utilization of materials, devices
and systems through the control of matter at the length scale of 1 to 100 nanometer (nm),
i.e. at atomic, molecular or supermacromolecular level.1 Yet, materials or structures with
at least one dimension below 100 nm also enter into this definition. Materials built at this
size scale (i.e. nanomaterials) often exhibit distinctive physical and chemical properties
due to quantum mechanical effects and/or large surface-to-volume ratio.
Since last decades, a variety of nanomaterials has been developed for both research and
industrial applications. For example, zinc oxide nanocrystals have been fabricated and
incorporated to sunscreens for blocking ultraviolet light; and silver nanoparticles have
been coated or embedded in bandages to kill microbes and prevent post-surgery infection.
Possibilities of application of nanomaterials are numerous, from producing energy saving
battery for vehicle, to manufacturing materials with anti-corrosion and scathing surface;
from fabricating chemical and biological sensors for health care, to environmental safety
solar-energy panels.
In recent, nanomaterials, in particular nanoparticles (NPs), offer immense potential for
various biomedical applications from drug and gene delivery to imaging, sensing and
diagnostics (Table 1.1), depending upon the nature of the materials and their chemical
and physical properties. Of all biomedical applications, the development of nanoparticles
based imaging agents for cancer therapy and biosensor for diagnostics stand out as the
most prioritised areas of research.
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Table 1.1 Typical inorganic nanoparticles and their general applications in biomedicine
Category

Examples

Intrinsic properties

Metallic NPs

Gold or
Silver NPs

Surface plasmon
resonance (SPR),
Surface reactivity,
catalysis.

Semiconduct
NPs, or/
Quantum dots

CdSe, CdS,
CdTe

Fluorescence,
Luminescence

Fe3O4, Co,
FePt NPs

Superparamagnetic,
Large magnetic
moments in a
magnetic field

Magnetic NPs

3

Biomedical applications
Chemical/biochemical sensing,
disease diagnostics; Optical
imaging, Raman probe;
photothermal cancer therapy;
drug delivery; antimicrobial
agents.
High-resolution and sensitive
cellular imaging; long-term cell
trafficking; diagnostics and
sensing based on energy transfer
techniques.
Magnetic separation for
diagnosis and monitoring; target
delivery of drugs & genes; MRI
contrast agents; Thermotherapy.

1.1.1 Nanoparticles as imaging agents and biosensing transducer
Molecular imaging and image-guided therapy is now emerging as a most promising basic
tool for monitoring disease. A variety of imaging modalities such as optical imaging,
magnetic resonance imaging (MRI), X-ray and ultrasound has been established for
diagnose disease and cancer therapy. Yet, these techniques are generally not sensitive
enough to detect tissue changes at molecular level that are usually the first signs of
evolution of healthy body to diseased ones. Further improvement of imaging involves the
design of novel contrast agents. The discovery and understanding of nanomaterials with
unique size dependent physical and chemical features has drawn the attention of research
in using nanoparticles as new contrast agents.
The current types of NPs widely used as imaging agents are luminescent nanoprobes for
optical imaging and magnetic nanoparticles for MRI. For example, the plasmon
absorption and scattering properties make the use of gold nanoparticles in targeting and
imaging of cells and cancer makers.2 Quantum dots (QDs) have been demonstrated to be
excellent

agents

for

optical

imaging,

because

of

their

bright

and

stable

photoluminescence. In particular, the tunable emission spectrum allows QDs emission at
near-infrared light (700 nm -900 nm) which could effectively penetrate in deep tissue.
Superparamagnetic properties of magnetic NPs provides contrast enhancement by
facilitating MRI signal strengths for non-invasive imaging.3, 4
Likewise, research in development of NPs based biosensors has showed highly
fascinating and promising results in the early and accurate diagnosis of clinical
conditions. For example, high surface to volume ratio of the nanomaterials enables the
detection of biomolecules under extremely low concentration by using optical,5 electrical
or electrochemical signal.6 Size-dependent physical and chemical properties make the use
of NPs for high throughput labelling and detection of bioanalytes.7,

8

Furthermore,

superparamagnetic NPs based systems that can be automated and miniaturized, which
provide enormous advantages over others for their potentials use in field situations.9, 10
Due to these great advantages, a number of nanosensors have now been developed in
detection of proteins, nucleic acid, bioactive molecules, bacterial and viral agents.11, 12
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A sensor generally consists of two components: a recognition element for target
recognizing and a transducer to convert the biological events into measurable signal
(typically optical signal). Bio-labelled NPs usually have been demonstrated to be
excellent transducers. In this case, NPs with unique optical property can be directly
labelled with a biological recognition element such as nucleic acid probe, antibody,
enzyme, aptamer or small bioactive ligands for detection.13 The concentrations of the
analytes are thus linked directly to the changes of optical signal.

1.1.2 Fluorescence resonance energy transfer as readout
Apart from providing signals for directly labelling in sensing and imaging applications,
NPs can also provide fluorescent signals in the form of Förster/fluorescence resonance
energy transfer (FRET), which is a process that nonradiative energy transfer occurs from
an excited fluorophore (donor) to a proximal ground state fluorophore (acceptor). This
process results in reduction of donor fluorescence intensity and increasing of acceptor
emission intensity (Figure 1.1).14,

15

The efficiency of energy transfer is strongly

dependent on the distance between the donor and acceptor. By measuring the efficiency
of energy transfer (e.g. through the changes of fluorescent signal from either donor and/or
acceptor), one can determine the distance between two fluorophore-partners. Based on
this, FRET has shown as a powerful tool for probing biological interations, sensing
analytes and imaging applications.
The pair of donor and acceptor in conventional FRET system can be organic dyes pair
(Cy3-Cy5), fluorescent proteins pair (e.g. cyan fluorescent protein and red fluorescen
protein pair), or dye-fluorescent proteins pair. Fluorescent NPs, such as QDs can also be
used in FRET system. For example, by taking the advantage of broad absorption spectra
and tunable emission profile, QD is particularly suitable as a donor in the FRET
system.16-18 Numerous investigators have utilized the QD-based FRET system for various
applications, such as detection of pathogenic DNA and DNA point mutation,19,

20

immunoassay,21, 22 tracking and quantifying enzyme activity,23-26 protein conformation
changes,27, 28 sensing pH 29 and ion changes,30 and interaction between of biomolecules.28
In some cases, the system was also used for multiplex detection of analytes.31

5

QDs can also be energy acceptor, particularly while incorporated into bioluminescence
resonance energy transfer (BRET)

32

and chemiluminescence resonance energy transfer

(CRET),33 whereby non-radiative energy transferring from substrate catalyzed by enzyme
and chemiluninescent donor to QDs, respectively. The major advantages for those
systems are low background noise and high excitation efficiency, as there is no need for
an extra excitation source, typically high-energy laser. In this way, in particular, QD
based BRET system has showed great potential in deep tissue imaging with low harmful
effect on bodies.32

Figure 1.1 Schematic illustration of FRET process
Nanomaterials with special surface chemical properties can be used as a quenching
energy acceptor incorporating in the FRET system. Au NP was used as a quencher for
QD based FRET probe in a multiplexed assay in detection of the activity of enzymes and
their inhibitors. 25
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1.2 Limitations of using NPs in biomedical fields
Despite that colloidal inorganic NPs offer immense promise for biomedical applications,
several concerns remain to be addressed.
The primary concern probably is the stability of NPs in water, as most biochemical
process occurs in aqueous environment. However, generally used methods usually
provide nanoparticles with hydrophobic ligands, meaning they are unstable in aqueous
solution. Another important concerning is the potential health and safety issues while
exploring nanomaterials to human body and environment. The determinants of particle
toxicity are known to be the large surface area and chemical reactivity in relation to small
size (and thus the ability to generate reactive oxygen species) and the capability to
penetrate tissues and cells.34 Thus, particles in nano-scale are likely to be more hazardous
than their bulk compartments, and free particles more toxic than fixed ones.35 One of the
examples to be considered is the potential cytotoxicity of QDs, because the heavy metals
core is toxicity, and particularly at high concentrations they could cause harmful effects
on embryo development and cell viability and function.36 Lastly, a nanoparticle must be
conjugated to a well-defined biological molecule, such as antibody, receptor, enzyme or
nucleic acid, for targeting application. Hence, there exists a gap between the nature of
NPs and their uses in biomedicine.
One method to bridge such a gap is the surface functionalization of nanoparticles (Figure
1.2). A proper surface coating can stabilize particles and avoid agglomeration, which
hence may increase the sensitivity of NPs based sensor. In addition, a proper surface
coating enables the nanoparticles in response specifically to biological species and avoids
non-specific interactions with components in the complex matrix. Coating is also an
effective manner of preventing the dissolution and release of core materials that may
cause toxicity to biological system.37 Furthermore, the steric hindrance of coating can
affect the fate of NPs in biological system, such as cellular uptake and accumulation,
circulation and clearance from body.38-40 In addition, the surface can affect the
maintenance of the intrinsic nanocrystal properties such as fluorescence and magnetic
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behaviour. Moreover, appropriate surface functionality is the perquisite for conjugating
biomolecules to NPs for biomedical applications.

Figure 1.2 Strategy for bridging the unique feature of nanoparticles to biomedical
applications.

1.3 Aims and Objectives
In view of the above overview, the overall objective of current research projects is to
design and develop advanced NPs with suitable surface for cellular imaging and
biosensing applicatoins. Several goals are set up to fulfill the objective as showed below.
(1) To develop hybrid fluorescent nanoparticles with unique proton resistant property

for cellular imaging application.
(2) To synthesize and prepare bioconjugated magnetic fluorescent nanoparticles for

simultaneous capture, detection and deactivation of bacteria for infectious disease
control.
(3) To develop sensitive and fast responsible luminescent nanosensors for disease

early diagnostics
To achieve these goals, the following specific objectives are sought in various chapters of
the thesis:
•

Chapter 1: Introduction
This chapter provides an overview of biomedical application of NPs, the outline
of objectives and the layout of the thesis.

•

Chapter 2: Background and Literature Review
This chapter presents a general review of strategies for surface functionalization
and bioconjugation of colloidal inorganic nanoparticles.
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•

Chapter 3: Development of biocompatible luminescent nanoparticles for
bioimaging applications.
This chapter presents preparation of biocompatible polymer-quantum dots hybrid
nanocomposites and their potential application in bioimaging. Two approaches
were developed to produce the nanocomposites. In particular, multiple layer
coating NPs prepared by the second approach shows its advantages in stabilizing
QDs luminescence in term of intensity and lifetime among different pH range.

•

Chapter 4: Development of bioconjugated magnetic luminescent nanoparticles for
bacterial capture, detection and antibacterial applications.
This chapter describes preparation of antibiotic gentamicin functionalized
fluorescent magnetic nanoparticles. The nanoparticles have a fluorescent
silica/iron oxide core/shell structure. The gentamicin conjugated fluorescent
magnetic nanoparticles shows an all-in-one method for capture, detection and
deactivation of both Gram-negative and positive bacteria.

•

Chapter 5: Luciferase conjugated nanoparticles for biosensing applications.
Following the success of my developed advance nanoparticles, in this chapter, I
extended the application of bioconjugated fluorescent nanoparticles into
nanosensors. The detection manner is based on energy transfer from
bioluminescence from enzyme catalytic reaction to gold nanoparticles. We found
the nanosensor could detect thrombin at nano-gram range in 15 min from both
buffer and human urine samples.

•

Chapter 6: General discussion and recommendation.
This chapter provides a general conclusion of the above studies and
recommendations for future work on the surface modification and conjugation of
the nanoparticles.
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CHAPTER 2
BACKGROUND AND LITERATURE REVIEW

2.1 Colloidal Inorganic
Application

Nanoparticles

for

Biomedical

Colloidal inorganic nanoparticles (NPs) are small objects sized between 1 and 100
nanometers (nm) that can be dispersed in a solvent. During the last two decades, colloidal
NPs have been attracting considerable interest from a wide range of disciplines, including
materials science, chemistry, physics, biology and engineering, because of their unique
physical and chemical properties. The change in those properties at this length scale from
their bulk counterparts can be attributed to a combination of scaling factors and nature
material of the NPs. These NPs can be composed of various materials including noble
metal, semiconductor, magnetic compounds and a hybrid of them.
The biomedical utility of colloidal NPs can arise from a variety of attributes, including
their physical properties such as optical (absorption or emission of light) and magnetic
properties.1 In addition, as biological processes generally occur at molecule level, the
similar scale of NPs makes it a suitable platform for investigating those processes. For
example, biomacromolecules surface recognition by NPs offer a potential tool for
studying transcription regulation, enzymatic inhibition, delivery, sensing etc.
The aim of this chapter is to give a brief introduction of NPs of biomedical use and
current strategies of surface functionalization and bioconjugation of colloidal inorganic
NPs with a special focus the NPs with optical (semiconductor NPs, such as QDs) and
magnetic properties.

2.1.1 Noble metal NPs
Noble metal NPs such as gold NPs and silver NPs are an important class of nanomaterials
used in biomedicine due to their unique surface plasmon resonance (SPR) absorption.
The SPR is caused by the interaction between incident light and oscillation of electron
charge on the surface of NPs (Figure 2.1).
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Figure 2.1 Schematic illustration of the SPR effect. The electromagnetic field of the light
induces a coherent dipole oscillation of the metal conduction electrons across the
nanoparticle (Adapted from Ref 2).
The response of noble NPs to oscillating electric field can be described by Mie theory, if
the diameter of a spherical NPs is much smaller than the wavelength of the incident light
(λ).3, 4 As shown in equation 2.1, the extinction cross section (Cext) of a particle (radius of
R), which defines the energy loss in the direction of incident light due to both absorption
and scattering, is described in term of dielectric function of the metal (ε = ε’+ iε”) and
dielectric constant of the medium εm.3 For small size of Au NPs (<60 nm), the absorption
cross section dominates in the Cext.5
Cext =

3/2

24π2 R3 εm
λ

ε"

2

�ε′ +2εm � +ε"2

Equation (2.1)

where ε = ε’ + iε” is the wavelength-dependent, complex dielectric function of the NPs
material and εm is the dielectric constant of the surrounding/embedding medium.
The frequency of SPR is thus dependent on the size and composition of NPs, as well as
the dielectric constant of medium. The change in SPR frequency yields the change of
NPs color that can even be observed through bare eye. The SPR frequency is strongly
sensitive to the dielectric constant (ε) of the surrounding media, such as surface ligand
changes and inter-particle aggregation. This great sensitivity makes Au NPs and Ag NPs
well suited for bioassay applications. For example, analytes such as DNA, metal ions and
antibodies can be detected by observing the visible color changes due to Au NPs
15

aggregation.6-8 Other examples are reviewed elsewhere including utilizing surfaceenhanced Raman scattering (SERS) for sensing.9,

10

In addition, the maximum

wavelength of SPR absorption for Au NPs fall into the visible range (520 nm to 600 nm),
which makes Au NPs as an excellent quencher to some common fluorophores for
bioimaging and biosensing application via resonance energy transfer process.11
Au NPs also find their applications in assisting drug delivery and therapy, due to the high
absorption cross-section. For instant, Halas et. al., reported near-infrared light triggered
gold nanoshells loaded hydrogels for deliverying a soluble drug.12 The mechanism is that
heat generated from the absorption of light by Au NPs triggered the hydrogels to collapse
and subsequently caused the release of the drug. Based on the similar concept, recently,
functionalized Au NPs or Au-hybrid NPs have been shown as a versatile tool for
photothermal cancer therapy

13, 14

and thermal ablation of pathogens.15 It is a great

advantage for such applications operating at NIR region, a transparent window for blood
and other types of biological samples.

2.1.2 Semiconductor quantum dots
Quantum dots (QDs) are semiconductive and fluorescent crystalline particles that
typically have diameters ranging from 2 nm and 10 nm. Semiconductors have a valence
band filled with electrons and an empty conduction band separated by a band gap (Figure
2.2). An electron in the valence band can be excited into the highest level of the
conduction band by absorbing a photon with energy higher than the band gap energy,
leaving a hole of opposite charge in the valence band. An electron and its hole are
attracted towards each other by Coulomb force, and together form an exciton. The
distance between the excited electron and its hole is called the Bohr radius. QDs
fluorescence occurs when the excited electron reverts to its hole in the lowest level of the
valence band and emits a photon with equivalent to the band gap energy (lower than the
absorbed).
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Figure 2.2 Size dependent photophysical properties of semiconductor quantum dots.
As the diameter of QDs is in the same order as its exciton Bohr radius, the excitons are
squeezed, leading to quantum confinement effect. The energy required to excite the
electron can be estimated in equation 2.2,16, 17
∆𝐸 =

ħ2 𝜋2
2𝑅2
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(Equation 2.2)

where me is the free electron mass, mh is the hole mass, and ε is the size-dependent
dielectric constant, R is the particle radius, ħ is the reduced plank constant and E*Ry is the
effective Rydberg energy that is usually small. The first term is band gap energy obtained
by “particle in a box” model. The second and third term indicate Coulomb force and
spatial correlation effect, respectively. The implications of the equation are clear that the
energy of the QDsare dependent on their size due to the quantum confinement effects.
Typically, smaller particles exhibit higher band gap energy and blue-shift emission.
The size-dependent fluorescent properties of QDs are superior to that of organic dyes in
biomedical applications. Firstly, QDs possess broad absorption spectra while maintaining
the same emission spectra. In addition, the emission profile is narrow and tunable,
allowing for multiplexing labeling. Furthermore, the bright fluorescence and significant
resistant to photobleaching, ensure a high ratio of signal to noise while applying them in
imaging.
17

The pioneer work for utilizing QDs in biomedicine were reported by two groups in 1998,
demonstrating water-soluble bioconjugated QDs as an excellent labeling agent for cell
imaging.18, 19 Since then QDs have been tested in various biological applications due to
its bright fluorescence, including DNA array technology, immunofluorescence assays,
labeling in cell and animal biology.20 One benefit of using QDs as labeling agents is the
ability to excite and detect several species simultaneously using one single light source.21,
22

Besides severing as staining agents for bioimaging, QDs with bright fluorescence can

be also used to study the dynamic process inside living cells at molecule level .23 Apart
from directly labelling, the narrow emission profile makes QDs as excellent donors for
FRET based sensing and imaging (see also in Chapter 1). In addition to imaging, QDs
were also used as photosensitizing agents for photodynamic therapy (PDT).24

2.1.3 Magnetic Nanoparticles
Magnetic nanoparticles (MNPs) are a class of NPs, which commonly consist of magnetic
elements such iron, nickel and cobalt or their chemical compounds. The magnetic
properties in matter are generally the consequence of the response of electrons magnetic
moments (due to their rotation around nucleus and spinning up and down) to an external
magnetic field. As shown in Figure 2.3, the materials can be classified into three
categories including diamagnetic (zero net moment, repelled by external field),
paramagnetic (zero net moment, attracted by external field), or ferromagnetic (exist net
moment, attracted by external field), depending on their response to an external magnetic
field.25

Figure 2.3 The responses of materials to magnetic field.
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MNPs exploited in biomedical fields are commonly made of ferromagnetic materials. In
such materials, the unpaired electron spins of an atom are interacting, leading to a parallel
oriented magnetic moment and maintain a low energy state. The regions where the
parallel orientation occurs are called magnetic domains. For energetic reasons, the size of
the magnetic domain is usually smaller than the grain size. If the size of the magnetic
materials is reduced when only one domain is reached (ranging from ~20 nm to several
hundred nm), as in case of magnetic NPs, the magnetic behaviors are different from their
bulk materials.
In single domain particles, the electron spins rotate in unison, flipping the entire magnetic
moment of particles coherently and leaving a net magnetization and preferred aligned
direction. As the size of particle ( diameter d for spherical particles) is reduced, the
coercivity (Hc), which is the intensity of the applied field to overcome this magnetization,
drops to zero at the superparamagnetic limit dsp (typically less than 40 nm). In such a
case, particles that were originally aligned will have random directions at the
measurement time without external field, due to thermal fluctuations of energy kBT (kB is
Boltzman constant, T is measure temperature). For the same particles, their magnetic
behavior can be affected by temperature. If the superparamagnetic particles are cooled, at
certain temperature, the measurement time will be insufficient for complete magnetic
relaxation, i.e. the particles will exhibit hysteresis (Hc >0). This temperature is known as
the blocking temperature (Tb). For example, TB of 26 nm Fe3O4 NPs is about 300 K
(room temperature). Therefore, particles large than ~26 nm are predicated to exhibit
ferromagnetism, while smaller ones should have superparamagnetism.26
Blocking temperature can be affected by particle size. The relationship between them can
be obtained from Equation 2.3,27
𝑇𝐵 =

𝐸𝑎

𝑘𝐵 ln 𝑓𝑡

(Equation 2.3)

Where t is the experimental measuring time, Ea is the anisotropy energy barrier that the
magnetization flip has to overcome by thermal energy. The term in the denominator can
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be treated as constant. Ea = KV, where K is the anisotropy energy density constant and V
is the volume of particles. Thus, blocking temperature is size dependent.
Superparamagnetic NPs, in particular iron oxide MNPs, are widely designed for preconcentration, separation, and identification of molecules and specific biological units
and are particularly suitable for integration in micro fluidic devices.28, 29 Additionally, the
advantages of a very large surface area and good biocompatibility make these NPs
suitable for integration with biological system.
The most important utilization of MNPs is separation and targeting of analytes.
Numerous reports took the advantage of immuno-separation by antibody functionalized
MNPs in detection of bacteria. In one example, Mujika and co-workers reported a
magneto-resistive immunosensor for the analysis of Escherichia coli O157:H7 in food
and clinical samples. This biosensor enabled to detect and quantify small magnetic field
variations caused by the presence of superparamagnetic particles bound to the antigens
previously immobilized on the sensor surface via an antibody–antigen reaction.30
However, different methods for detection of MNPs become more and more important
while incorporation with immuno-separation. Other common reported detection methods
are impedimetric measurements

31

and electrochemical magneto-genosensing.32 In the

latter case, Liebana and colleagues reported the integration of immunomagnetic
separation/double-tagging

PCR/electrochemical

magneto-genosensing

to

detect

Salmonella in skimmed-milk samples with a limit of detection (LOD) of 1 colony
forming-unit (cfu)/mL. By combining the magnetic separation and miniature technology,
individual cells can now be separated through a microfluidic device system and
visualized in a low power microscopy.33 Another important aspect for taking the
advantage of magnetic attraction property is the transport of drugs and gens by magnetic
NPs. MNP medicated drug delivery can be performed via passive, active or direct ways.34
Research work about the functionalization of MNP with emphasis on the active in vitro
or in vivo drug delivery and related recent clinic results are reviewed by Pankhurst et.
al.35
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In addition to separation and identification of target from matrix, MNPs have recently
been used as labels in biosensing and bioimaging. For example, Koets and co-workers
reported using streptavidin-coated superparamagnetic particles as detection labels for E.
coli and Salmonella via a Giant Magneto Resistance (GMR) sensor.36 An important use
of MNPs now is for magnetic resonance imaging (MRI) application where the NPs are
introduced as contrast-providing agents which have been summarized elsewhere.37-40
Despite of few examples, MNPs can also be used as antiseptic agents. There are main
two methods to modify magnetic NPs to obtain the antimicrobial NPs. The first one is to
functionalize NPs with biomolecules of antimicrobial activity. For example, in the study
conducted by Kaittanis, C. et. al., Con A-conjugated polysaccharide magnetic NPs have
been shown with significant and fast inhibition of the growth of E. coli and S. marcescens
in blood culture.41 In another work, Chen et. al. reported that the immobilization of
antimicrobial peptide LL-37 on the surface of polyacrylic acid coated NPs can effectively
kill E. coli.42 The second method to enable magnetic particles with antimicrobial
properties is to coat them with inorganic/organic antibacterial layers. For instance, silver
NPs and TiO2 layer have been deposited onto the surface of magnetic particles to produce
antibacterial agents.43, 44

2.2 Synthesis of colloid NPs for biomedical use
Colloidal inorganic NPs can be synthesized by various physical and chemical methods,
with the particles differing in their elemental composition, shape, size and chemical or
physical properties.45 The physical methods in general involve vapor deposition
approaches which dependent on sub-dividing of bulk materials to smaller NPs. Typical
chemical ways involve the reduction of ions into atoms in the presence of stabilizing
agents, followed by controlled growth of atoms into NPs (so called “bottom-up”
process).46 In the case of biomedical applications, solution based chemical synthesis
methods have been proved preferable ways, as they are more effective to control the size
distribution and ready for further modification or conjugation with biological species. In
this way, as-synthesized NPs are dispersed in a solvent either water- based or an organic
solvent for hydrophilic or hydrophobic particles, respectively; meanwhile amphophilic
NPs can be dispersed in both kinds of solvents.
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2.2.1 Synthesis of NPs in water
A variety of NPs including Au, 47, 48 Ag,49 Co,50 Fe3O4,35 Fe2O3,51 SiO2 52 and CdTe 53, 54
have been synthesized in aqueous solution. These methods produce water-dispersible
NPs, a necessity for the application in biological systems. One typical example is the
synthesis of noble metal NPs such as Au NPs by reduction of Au(III) salts using reducing
agents such as sodium citrate, citric acid, ascorbic acid or amines.55 In addition,
biomolecules (e.g. starch) are also used as reducing agents providing a green protocol. In
another way, aqueous co-precipitation process, which involves nucleation growth,
coarsening and /or agglomeration, has been widely used in preparation of metallic and
metal (hydr) oxides NPs. The composition and morphology of the NPs are controlled by
precisely adjusting the reaction parameters.56 Stöber method, an aqueous sol-gel process,
is established to synthesize SiO2 NPs.52 Success has also been achieved in synthesis of
water-soluble semiconductor CdSe and CdTe quantum dots.54 However, limits in
controlling a narrow size distribution and low ordered crystalline structure remain as
main challenges, which subsequently affect their physical properties and stabilities.

2.2.2 Synthesis of NPs in organic phase
NPs composed of noble metals, transition metals, oxides and semiconducting materials
have been synthesized in organic phase via a thermal decomposition process. The process
general involves high temperature thermolysis of metal-organic precursor in the presence
of a hydrophobic capping agent, as well as in a non-polar organic solvent. The resultant
NPs usually gain high quality of nanocrystals.57 The growth of NPs, the crystal structure
and the cessation of growth depend on the environment and are fundamentally regulated
by the hydrophobic ligand. These ligands are either surfactant species such as fatty acid
or alkane thiols. The obtained NPs are thus inevitably hydrophobic. The ligands in some
cases also serve as solvent. One example is using tri-n-octyl phosphine oxide (TOPO) for
capping the semiconductor quantum dots.58
Hydrophilic NPs can also be produced in one-pot synthesis in organic phase by using
dedicatedly selected stabilisation ligands. For instant, amphiphilic ligands such as
peptides

50

and thermo-responsive polymers

59

22

have been used in preparation of Co NPs.

However, only few examples have been reported due to the limit of amphiphilic
materials.

2.3 Surface Functionalization of NPs
A large portion of NPs used in biomedicine is produced in organic phase through high
temperature process. High-temperature synthesis in organic phase offers a number of
advantages over aqueous synthesis. Firstly, high temperature allows the impurities of NPs
be annealed out to obtain good crystallite structure. Furthermore, long chain of organic
ligands enables steric stabilization of NPs and allows higher concentration of NPs to be
produced. Moreover, temperature can be used to manipulate the morphology and size of
the NPs through controlling the growth kinetics of crystals. However, the resultant NPs
with apolar ligand are only soluble in organic solvents, e.g., hexane, toluene or
chloroform. They usually cannot be used directly for most applications in biomedicine, as
most biological process occurs at aqueous environment. Therefore, it is necessary to
bring them with water solubility, prior to the use them in biomedicine. One method to
circumvent this problem is development of strategies for surface functionalization of
NPs. Such strategies should satisfy certain criteria: i) they can enable NPs with good
water solubility, ii) they should offer a reduction of toxicity of NPs in some instances, iii)
they can provide additional functionalities for further conjugation of biomolecules for
targeting applications, and iv) they can stabilize the physical properties of NPs. Here a
variety of strategies for surface functionalization of NPs are evaluated and compared to
their effect on parameters relevant to stability, nonspecific binding, and biocompatibility
of NPs. The discussion falls in three categories: ligand exchange, ligand modification and
ligand addition (encapsulation), as shown in Figure 2.4.
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Figure 2.4 Schematic illustrations of common surface functionalization strategies.

2.3.1 Ligand exchange
For biomedical applications, ligand exchange of NPs usually involve a process that the
initial hydrophobic ligands are replaced by other more strongly bonding hydrophilic
ligands that allow the transferring of NPs from organic phase to aqueous solution. A
number of hydrophilic ligands have been reported to exchange the nature ligand on the
surface of NPs and bring them to aqueous solution, including small molecules with
functional headgroups (e.g. thiol, carboxyl, amine, phospine group, etc.), PEG derivatives
and biological molecules (Figure 2.5).
Small molecules. Small molecules with high affinity head functional group are primary
candidates for generating water-soluble particles, as they produce NPs with a smaller
hydrodynamic radius, which promotes in vivo trans membrane permeation and excretion
of NPs.60 Common examples of small molecules are alkylthiol terminated molecules that
can strongly bind to the inorganic surface of NPs, e.g. Au and Ag 61 or CdSe QDs,18, 62-65
by replacing weaker ligands. However, the colloid stability of the resultant NPs in buffer
solution is often poor which is partially attributed to the desorption of ligands from
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NPs.64 To overcome this problem, bidentate ligands such as dihygrolipoic acid (DHLA)
and dithiocarbamate ligands are used to stabilize the NPs by increasing the number of
anchor points to particle surface.66-68 In addition to alkyl thiol terminated ligand
molecules, many molecules with other functional headgroups have also been developed
to transfer NPs from organic phase to aqueous solution. Excellent examples include
tetraalkylammonium salts such as tetraoctylammonium bromide (TOAB) for transfer of
AuNPs, and hexadecyltrimethylammonium bromide (CTAB) for iron oxide NPs;69,

70

oligomeric phosphine (oxide) ligands for transfer TOP/TOPO capped QDs;71 amphiphilic
species such as 2, 3-dimercaptosuccinic acid (DMSA)

72

and cyclodextrin

73

for

transfering of oleic acid capped NPs, respectively. However, one drawback is that the
small ligands rely on electrostatic interaction to stabilize NPs. Therefore, when the
solution condition such as pH and salt concentration changed, the NPs may be “salting
out” and forming aggregation.

Figure 2.5 Common ligands for stabilizing NPs in water.
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PEG derivatives ligands. An alternative is using polymeric ligands as ligand exchange
agents to overcome the poor colloidal stability of NPs that capped by small molecules. A
number of polymers have been reported to offer NPs with good stability and water
solubility. Among them, poly (ethylene glycol) (PEG) is the most common reported
ligands for stabilizing NPs especially in biomedical applications. The ether group in the
backbone of PEG chains utilizes hydrogen bonding and steric stabilization for water
solubility, instead of electrostatic interactions. It is thus expected that PEG based NPs
would confer well stability over a wide pH range and even at high salt concentration.
Taking advantage of this, Mattoussi’s group developed a set of DHLA-PEG derivatives
for capping QDs through ligand exchange.74, 75 As a result, by combining the benefit of
strong bonding through dithiol moiety to particle surface, the PEG based QDs confer
water solubility over a wide pH range and high salt concentration. In addition to good
particle stability, PEG based NPs also were also found with low degree of nonspecific
binding to biological components, less cytotoxicity and longer circulation time in vivo.76,
77

Due to those advantages, it has been now increasing common to use PEG segments for

capping NPs to improve the biocompatibility.78 However, it should note that PEG itself is
simply a polyether, in general it should be modified with reactive terminal functional
group to serve as an anchor to the NPs.
Biomolecules. Other exchange ligands involved are biomolecules such as sugars, peptide,
nucleic acid and their derivatives. In one example, glucose and sucrose have been used in
reduction and post-synthesis stabilization of Ag and Au NPs in aqueous salts.79 Small
peptides are also used as QDs surface ligands. Pinaud and co-workers developed
phytochelatin-like peptides replacing TOPO for coating CdSe/ZnS QDs.80 The advantage
to use peptides as surface ligands is they offer an all-in-one solution for particles
solubilisation and biofunctionalization. Several other examples will be discussed in the
biofunctionalization part.

2.3.2 Ligand modification
A different strategy from ligand exchange is in situ modification of ligand for phase
transfer, which can prevent NPs aggregations due to irreversible desorption of replaced
ligands. This strategy can be achieved by either modifying a compound that can change
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the polarity (e.g. oxidation of oleic acid to form carboxyl group or vicinal diol

81

), or

addition of hydrophilic agent which can interact with the hydrophobic ligand (e. g.
formation of a complex of cyclodextrin with oleic acid,73 or covalent conjugation with
amphiphilic agents (e. g. conjugation with V-shaped ligand 82). Despite of high efficient
phase transfer, this concept is merely limited to certain systems.

2.3.3 Ligand addition
Ligand addition involves an addition of the external surface of the NPs shell without
removal of any initial ligands. The strategies include addition of a layer of inorganic
materials and encapsulation of a layer by intercalating hydrophobic polymers into the
initial hydrocarbon shell of NPs.
Inorganic core-shell structures. One of the major challenges for functionalizing NPs is
find a common agent/ligand for ubiquitously capping the NPs. However, as for organic
molecules capping, it is necessary to select specific head groups of ligands that have high
affinity the NP core. This will limit its applications. Alternatively, coating NPs with an
inorganic layer/shell for which the ligand has a high affinity is of great interesting.
Materials, such as noble metal (Au and Ag), semiconductor (e.g. ZnS) and silica, have
been used as NP shell to protect the core, add functionality or introduce chemical group
for further functionalization.
Probably, one of the most widely used methods for surface coating of NPs is silica
coating. The advantages silica coating includes enhanced water soluble, good colloidal
stability, low non-specific interaction and biocompatibility.83 A typical process to grow a
silica shell around NPs involves firstly exchanging of hydrophobic ligands with primer
molecules, such as 3-(trimethoxysilyl) propyl methacrylate (MPS) and 3-aminopropyltriethoxysilane (APTS) by selection of the precursors specific for each NP material. Then
the growth of a amorphous silica shell can be processed via hydrolysis of sodium silicate
(Iler process) or tetraethoxyxillane in alcohol (Stöber method).84, 85 A modified method
involving the base-catalysed hydrolysis of tetraethyl orthosilicate (TEOS) has now been
widely used. One advantage of this method is the capability of controlling of silica shell
thickness by simple adjusting the ratio of component in the reaction mixture
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(ethanol:water).86 The pH is very important for hydrolysis of TEOS. Mildly alkaline pH
(7.5) is found as the optimum point for formation of core-shell structure.
Using the same chemistry, secondary silanes with ionizable hydrophilic groups can be
introduced on the initial silica shell to render NPs hydrophilic or add chemical
functionality. For example, incorporation of PEG chains can improve the stability and
biocompatibility of the silica coated NPs. Functionalization with APS and MPS can
facilitate the covalent binding with biomolecules through amine and thiol group,
respectively. Mesoporous silica can also grow on the surface of NPs, just after the
formation of a thin layer of amorphous silica as describe above. Cationic surfactants such
as CTAB have been used as templating materials to synthesize mesoporous silica shell on
NPs surface.69,

87-89

The mesopores allow loading of drugs such as doxorubicin and

ibuprofen to serve as devilry cargo.89, 90
So far, the silica shell have been successfully deposited on a variety of colloidal particles
of metals,84, 91-93 metal oxides,94, 95 and semiconductors.19 However, the growth of silica
shell in general results in increasing of the hydrodiameter of the NPs, which consequently
may affect the physical properties of NPs, e.g. deterioration of saturation magnetisation
whiling coating magnetic particles.96 In addition, polymeric silica present in the NPs
surface can cause NPs aggregation by slow hydrolysis process without further surface
modification.97
Polymer encapsulation via hydrophobic interactions. Polymer encapsulation involves
over-coating hydrophobic ligand capped NPs with amphiphilic polymers. The
encapsulation is achieved by intercalating the hydrophobic portion of polymer with the
initial ligand on the NPs surface and rendering hydrophilic portion towards the solution.
Head groups, such as carboxyl or amine groups, and/or PEG segment within the
hydrophilic portion of the polymer, bring NPs water solubility. The functional group can
further allow for bio-conjugation or bio-modification of NPs. Initially, phospholipids,
which can form micelles with 5 nm hydrophobic interior, were used to over-coat TOPO
capped NPs and render them water-dispersibility.98-101 However, the resultant NPs
suffered from poor stability because of desorption of the relative weak anchoring
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phospholipids from the NPs. To improve the stability, low water-soluble fatty acids were
used to generate lipid bilayers coated NPs.102 An alternative is using amphiphilic coblock polymers, of which a single polymer contains multiple hydrophobic side chains to
enforce the hydrophobic interaction. Wu et. al., developed a co-block polymer for coating
TOP/TOPO capped QDs.103 The strategy involves appending a poly(acrylic acid) (PAA)
back-bone by hydrophobic octylamine chains through EDC mediated conjugation,
following by coating to QDs. In their report, 40% of the carboxylic group of on the PAA
back-bone were converted by hydrophobic alkyl chain. The octylamine chains then
intercalated into hydrophobic TOP/TOPO ligands on the QD surface, and the remaining
negative carboxylic groups could then promote the particle water-soluble. Some other
amphiphilic co-polymers such as poly(maleic anhydride aIt-1-tetradecene)
PEGylated polymer

105, 106

104

and

were also reported to generate hydrophilic QDs. The

significant advantage of using polymer coating is that, theoretically, a wide range of
different NPs can be transferred into water with one optimal amphiphilic polymer. The
over-coated NPs in general can also benefit from excellent colloidal stability over a wide
pH rang and at high salt concentrations.

2.4 Bioconjugation
Surface functionalization can render NPs water-solubility, functionality and stability in
physiological environment. After that, NPs are required to conjugate with biomolecules
of interest (e.g. small bioactive molecules, peptide, proteins, nucleic acid, etc.) for further
biomedical applications. Many conjugation strategies have been developed. Here some
common used methods are discussed below (Figure 2.6).

2.4.1 Direct absorption
Biological species can interact directly with different kinds of NPs. Non-specific staining
of certain celluler structure may be achieved by injecting hydrophilic NPs into
cytoplasm.107 The NPs even without additional functionalization have been shown to
attach to certain place inside cell.108 However, the interaction is usually weak and nonspecific, and has limited uses. Instead, the signal generated from non-specific interaction
may interfere with the real measurement. Thereby, the direct absorption of biomolecules
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by NPs mentioned here refers to the specific attachment of certain biological molecules
to NPs with relative strong non-covalent interaction.
Biomolecules with special functional groups can be directly linked to NPs. For examples,
thiol groups from cytosine amino residue can be used to coordinated peptides or proteins
to noble metal NPs

109

and QDs.110 Similarly, DNAs oligos terminated with thiol group

have also been labelled to those NPs.63, 111, 112 Furthermore, metal-affinity driven selfassembly is also utilized for the conjugation of biomolecules to NPs. One example is
polyhistidine (six histidine residues) tags (His tag) can allow strong and reversible
conjugation of proteins or peptides on the Ni-nitrilotriacetic acid (Ni-NTA) modified
NPs.113-115 More interesting, His tag appended protein were also found to directly
coordinate with the metal zinc ions of the ZnS coated QDs.116
A different approach is the absorption of biomolecules to NPs surface via electrostatic
interactions. For instant, negatively charged nucleic acid can be attached to the positive
charged surface of NPs.117, 118 Proteins, which have a natural positive (or negative) charge
under physiochemical environment, can also adhere to NPs with negative (or positive)
charges. Others neutral charged proteins could be engineered with charged domain to
enhance the adsorption to NPs surface. Mattoussi et. al., have engineered maltose binding
protein (MBP)

66

and protein G with a positively leucine zipper domain.119 The

engineered proteins can then adhere to the surface of DHLA capped QDs. As the
attachment is mediated by electrostatic interaction, the conjugation is simple dependent
on the surface charge of NPs, regardless of the material of NPs. There are, however,
some drawbacks with this approach, including sensitive to pH and salt concentration,
high degree of non-specific binding, and required engineering of proteins in some cases.

2.4.2 Covalent coupling
Covalent coupling provide specific and stable conjugation of biomolecules with NPs.
Typically, functional groups on the NPs surface including carboxylic group, amide group
and thiol group can cross-link with biomolecules through various coupling strategies
(Figure 2.6). Some common strategies are discussed below based on the functional
groups involved.
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Figure 2.6 Representative bioconjugation protocols.
Amine group involved coupling. Probably the most commonly coupling methods for
bioconjugation of NPs involve amine functional group. Primary amine can react with
carboxylic group to form a “zero length” amide bonds. The linkage is usually mediated
by carbodiimide agents, such as most commonly used 1-ethyl-3-(dimethylaminopropyl)
carbodiimide (EDC) (Figure 2.7a). The conjugation strategy has been applied to coupling
of various proteins (e. g. enzyme and antibodies) ,18,
acid,124,

126

small molecules with amine groups,127,

120-125
128

amine-terminated nucleic

etc., to carboxylic group

functionalized NPs. Few cases are also found between amine functionalized NPs and
carboxylic groups on biomolecules. More specifically, the coupling efficiency can be
enhanced by addition of stabilising agents such as n-hydroxysuccinimide (NHS) or sulfoNHS by formation of a succinimide ester intermediate.129 A variation of this strategy is
using bis-NHS to cross-link two amines group.130
In addition to carboxylic group, the active nucleophilicity allows amine group to react
some other functional groups, such as aldehydes, thiol group, epoxides and isocynates.
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For example, glutaraldehyde was used to conjugate enzymes to NPs surface by bridging
two amines from each species.131 The space of the linkage is approximately 0.7 nm.132
Thiol group involved coupling. The thiol group can selectively conjugate with primary
amine groups. The reaction starts rapidly under the mediation of reagents such as
maleimides and iodoacetamides.133,

134

sulfosuccinimidyl-4-(maleimidomethyl)

Most commonly, the coupling reagent is
cyclohexane-1-carboxylate

(sulfo-SMCC)

(Figure 2.7b). To take advantage of this reaction, amine-functionlized NPs can be
conjugated with various thiolated biomolecules, including thiol modified peptide,135
residue thiol-teminated DNA,107 or peptides and proteins with free or reduced cysteine,136
or verse vice.137, 138 Disulfide bridges can be also used for reversible coupling of NPs. By
utilizing of glutathione (GSH) disulfide and dithiothreitol, Tian et al., showed reversible
oxidation and reduction of disulfide bridges between silica NPs and Fe3O4 NPs,139
respectively. The same approach was adapted for delivering and releasing of drug via
hybrid nanostructures, under the regulation of GSH.140
Click chemistry. Another common approach for bioconjugation is the so called “click
chemistry”. The reaction basically involves coupling of alkyne to an azide giving a 1,2,3triazole ring under catalyst of Cu (I). The process has been demonstrated to be highly
versatile and great potentials for bioconjugation of NPs.141 The one-step click process has
also been shown to give the possibility of introducing multiple functionalities onto
NPs.142 The limitation probably is that it requires special preparation of the azide or
alkyne-functional bioactive species, which is often involved a labor work and has low
yielding.143 Fortunately, now many commercial kits have been developed to simplify the
process and improve the products yield.144
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Figure 2.7 Reaction scheme for EDC-NHS crosslinking (a) and (b) SMCC mediated
conjugation.

2.4.3 Biological approaches
Biological processes are often completed by highly specific interactions of biomolecules,
such as antibody-antigen interaction, receptor and target interaction, enzyme and
substrate interaction, and complementary base pair of nucleic acid. It is thus possible to
take the advantages of those high specific interactions for bioconjugation of NPs. For
example, single oligo DNA functionalized NPs were used to specific recognize target
genetic materials.145,

146

Furthermore, DNA aptamers functionalized Au NPs were

reported to bind and response to different of analytes.147 Moreover, protein G
functionalized NPs have been used to immobilize IgG via interactions with Fc region of
the antibody, leaving the free Fab region for capturing staphylococcus bacteria.148 One of
the most common used biological interaction is the (strept)avidin-bintin interaction which
has a very high affinity (Kdiss > 1.3 x 1015 M). NPs can firstly functionalized with
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(strept)avidin via either electrostatic absorption or covalent coupling methods. After that,
the NPs can then used to label biotinylated peptides, proteins, antibodies and DNA.121, 149152

Antibodies and receptor/ligand biomolecules require a binding domain to be exposed

and accessible in order to be biological active. However, even taking advantages of high
specific interaction and high efficiency covalent coupling strategies, it is still a problem
to control the orientation of biomolecules attached to NPs.
To overcome the problem, recently expressed protein ligation (EPL) attracts some
interesting as it allows for site-specific conjugation of targeting molecules to NPs. EPL
refers to a native auto-processing chemical ligation mediated by a protein called intein in
biological system. The process involves a recombinant protein with a C-terminal thioester
and a second agent with an –N-terminal cysteine. This C-terminal thioester is usually
introduced by intein which can be cloned downstream of the target protein (Figure
2.8).153 A transthioesterification reaction occurs between thioester and amine of the
cystein, followed by a rapid S → N acyl transfer to form an amide. Several studies have
shown the versatile of EPL for site-specific bioconjugation of hydrazine nucleophiles
modified NPs with engineered proteins.154,

155

However, as the efficiency of the

conjugation depends on high concentration of both functional groups, it is relatively low
while applied in NPs conjugation due to low concentration of NPs used. To overcome
this problem, a two-step strategy was developed, which involvs ligation of azide (alkyne)
modified small nucleicphilic molecule with engineered protein by EPL, and followed by
conjugating of the azide (alkyne) linked protein with alkyne (azide) modified NPs via
click chemistry.156,

157

It is expect that this EPL can offer great opportunities for

conjugation of NPs with various enzymes or other proteins, particularly for biosensing
applications. The limitation is that it is still required to genetically modify proteins by
recombinant DNA technology.
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Figure 2.8 Mechanism of intein mediated bioconjugation.

2.5 Summary
Surface functionalization of NPs is considered as a prerequisite for their biomedical
applications. In general, an ideal surface should satisfy criteria such as providing good
water stability and chemical functionality for further functionalization, maintaining NPs
physical and chemical properties, and biocompatibility. Through the approaches
discussed above, ligand exchange involves a simple process, even without affecting the
particles size. However, it often compromises the stability of NPs, as the ligands tend to
dissociate from the surface leading to the particles aggregation. In the case of QDs, the
dissociation of ligand can result in decreasing of fluorescence efficiency. Polymer
encapsulation is of great advantage, as it results in better stability and preservation of NPs
physical properties (e.g. magnetization and photoluminescence). However, additional
steps are required for formation of polymer and hydrodiamter of polymer coated NPs is
usually large. In addition, the universal amphiphilic polymer to coat a wide range of NPs,
though possible, is still under research. Incorporation of PEG backbone can increase the
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biocompatibility. The drawback, however, is that encapsulation increases the particle size
significantly. Therefore, it remains a challenge to satisfy all the criteria.
On the other hand, directly coating peptide and protein on NPs are not often used, which
could achieve relative small hydrodynamic diameter of NPs. For example, absorption
relying on type of NPs and biomolecules with certain groups; meanwhile, electrostatic
assembly requires strict physiological conditions, to avoid dissociation and nonspecific
binding. Covalent bioconjugation approach probably is the most widely used
bioconjugation method as it forms stable linkages. However, the stoichimetry of
NPs/biomolecule is hard to control and it may cause self-assembly and biomolecules and
aggregation of NPs. In addition, the controlling of the orientation of biomolecules
immobilized to the surface of NPs is still a challenge. While biological affinity based
methods, such as antibody/antigen conjugation, offer highly specific interaction, the
drawback is it often leads to a large structure. Small protein mediated conjugation is
attractive, as the reaction is highly selective, similar to enzyme catalysis. The efficiency
may need to improve. It is anticipated that these biomacromolecules (such as enzyme or
bio-molecules likewise) will be promising agents for biofunctionalization of NPs in
future, just like they work inside of biological systems.
Therefore, the challenges remain in development of proper strategies in surface
functionalization and bioconjugation of NPs with enhanced chemical and physical
properties for desired applications in biomedicine.
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CHAPTER 3
DEVELOPMENT OF BIOCOMPATIBLE LUMINESCENT
NANOPARTICLES FOR BIOIMAGING APPLICATIONS
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3.1 Introduction
Group II-VI semiconductor nanocrystals, referred as quantum dots (QDs), have been
extensively studied as light-emitting materials for biological labeling over last decade,
because of their strong size-tunable bandgap luminescence.1-4 Cadmium Selenide (CdSe)
QDs are one of the most attractive QDs in bio-imaging due to their size-dependent
emission in a visible region as well as the high photoluminescence (PL) quantum yield,5, 6
However, CdSe QDs show the inherent biological toxicity

7, 8

and instability in aqueous

solution,9 which limit their in vitro and in vivo biomedical applications. A variety of
materials have been used to cap or re-cap QDs, including amphiphilic molecules,2, 10-14
polymers

15, 16

and inorganic silica shells,1,

17, 18

to enhance the stability and

biocompatibility of QDs. In particular, encapsulation of QDs in biopolymer not only
protects QDs from oxidation, but also provides a biocompatible layer to avoid the direct
interaction between living cells and the Cd- and Se- containing QDs core. In addition, a
great variety of functional groups could offer new chemical functionalities to QDs by
grafting bio-molecules.
Gelatin is a natural biocompatible biopolymer derived from collagen. Gelatin
nanoparticles (GNPs) have been used in gene delivery.19-21 Most recently, fluorescent
GNPs-encapsulating demonstrates the potential applications in drug delivery and bioimaging at the same time.22-27 Unlike loading organic dye, loading quantum dots (QDs)
within GNPs may improve the biocompatible of QDs and fluorescence properties of
GNPs. The two-step desolvation process initially developed by Coester et. al. is able to
produce well-tailored GNPs in terms of uniform size and narrow size distribution.20, 28
Previous reports indicate that the pH value above 3.0 may result in early agglomeration
of gelatin chains in the second-step of desolvation method.28, 29 However, it should be
noted that the PL properties of QDs in terms of PL intensity and lifetime normally decay
in acidic conditions, pH < 5, due to acid etching

10, 30

and/or surface state energies

modification.31-33 In this case, encapsulating QDs into GNPs by the desolvation method
might result in the quenching of QDs because of low pH value in the second desolvation
step. In addition, other defects such as colloidal instability and low quantum yields (QY)
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are hardly avoided in reported methods, e.g. in situ loading QDs onto GNPs in aqueous
media.22, 26
In this chapter, two approaches were presented for preparing hybrid CdSe QDs-gelatin
nanoparticles (QDs-GNP) nanosystem. In the first method, nanosystem QDs-GNP1 is
prepared by directly encapsulating hydrophilic CdSe QDs in NPs () via desolvation
method through carefully controlling of the medium pH. Fluorescent property and
biocompatibility were investigated. To improve the stability of QDs photoluminescence,
a second approach involving an electrostatic layer-by-layer (LBL) deposition process was
developed to prepare a novel multilayer gelatin/QDs core/shell NPs by assembly of
hydrophilic CdSe QDs on the surface of gelatin nanoparticles (i.e. nanosystem QDsGNP2). The advantage of using electrostatic LBL deposition method is that it has been
known as one of the simple and cost-effective methods for multilayer coatings.34-38 The
sequentially assembled polymers with opposite charges onto micro/nanoparticle
templates have demonstrated a great potential in fabrication of multifunctional core-shell
structures.34 The morphology, structure, pH stability in term of PL property,
biocompatibility, and potential applications in bio-imaging of the nanocomposites were
further investigated, respectively. The PL properties of the core-shell nanoparticles as a
function of the pH value are studied. In addition, the cytotoxicity of the luminescent
QDs-GNP2 has been investigated by using NIH/3T3 mouse fibroblast cell line. It is
expected that the new fluorescent core-shell QDs-GNPs can be an alternative fluorescent
contrast agent with stable photostability and superior biocompatibility.

3.2 Experimental procedures
3.2.1 Materials and Reagents
Type A gelatin from porcine skin (~300 g Bloom), cadmium acetate hydrate, selenium
powder (99.5%), trioctylphosphine Oxide (90%, TOPO), trioctylphosphine (TOP, 90%,
Aldrich), 11-Mercaptoundecanoic acid (MUA), tetramethylammounium hydroxide
pentahydrate

(TMAHP,

styrenesulfonate)

(PSS),

97%,

Sigma),

ethyl

polydiallyldimethyl

acetate,

ether,

ammonium

poly(sodium

chloride

4-

(PDAC),

glutaraldehyde (25%), 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI), and
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phosphate buffered saline (PBS, tablet) were purchased from Sigma-Aldrich (ST, Louis
MO). MultiTox-Fluor multiplex cytotoxicity kit was ordered from Promega (Madison,
WI). For cell culture, Gibco® Dulbecco's Modified Eagle's medium (DMEM) and FBS
were supplied by Invitrogen (Grand Island, NY). Glass bottom petridishes were supplied
by MaTek Inc (MA, USA).

3.2.2 Preparation of hydrophilic CdSe QDs
TOPO capped CdSe QDs were synthesized following a modification of procedure
described by Aldana et. Al.39 In brief, 0.5 g cadmium acetate hydrate mixed with 40 g
TOPO was heated to 330 oC under argon flow. A selenium stock solution consisting of
0.8 g selenium powder, 20 g TOP and 0.35 g anhydrous toluene was then injected rapidly
into the above mixture. The temperature was cooled down to 270 oC and maintained for 4
min. After that, the solution was cooled down to 30-50 oC. Excess amount of methanol
was added to the mixture to precipitate the QDs. The QDs were then centrifuged at 8000
rpm for 15 min. After repeating washing with methanol and acetone, the hydrophobic
CdSe QDs were dissolved in hexane and kept under dark.
The hydrophilic CdSe QDs were prepared by replacing TOPO from the surface of QDs
with MUA. In a typical experiment, 20 mg of MUA was mixed with 15 mL methanol
under dark conditions and argon flow. The pH of the mixture was then adjusted to 10.3
by addition of 200 mg TMAHP. Following that, 20 mg of the as-synthesized CdSe QDs
were added into the mixture. The mixture was further heated to 65 oC. After overnight
refluxing, the mixture was cooled down to room temperature. The QDs were then
precipitated by addition of excess amounts of ethyl acetate and ether (1:1). The QDs were
further washed and purified by centrifugation (5800 rpm for 5 min). Finally, the QDs
were re-dissolved in distilled water.

3.2.3 Preparation of gelatin NPs
Gelatin NPs were made by a two-step desolvation approach with slight modification.28
Briefly, 1.25g of gelatin type A powder was dissolved in 25 mL nanopure water under
constant heating at 40 oC. In order to achieve the desolvation of gelatin, 25 mL of acetone
was then added rapidly to this solution. The supernatant was discarded and the remaining
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high molecular weight (HMW) gelatin was re-dissolved by adding another 25 mL of
nanopure water at 40 oC. The pH of this solution was adjusted to 2.5. The gelatin was
then desolvated again by dropwise addition of 75 mL acetone during 15 min under this
constant heating. A white milk-like solution appears when 55 to 60 mL of acetone was
introduced into the mixture. After 10 min of stirring, 0.5 mL of 25% glutaraldehyde
solution (Sigma-Aldrich) was added to crosslink the particles. After another 30 min of
stirring, the dispersion was centrifuged at 6500 rpm for 10 min. The particles were
purified by repeating re-dispersion with acetone (30%) and centrifugation. After the final
centrifugation, the particles were freezing-dried overnight and kept at 4 oC for further
studies.

3.2.4 Preparation of QDs-GNP1 by direct encapsulation of QDs in
GNPs.
Figure 3.1 is a schematic illustration of the preparation of QDs-GNP1. Briefly, 1.25 g of
the gelatin powder was first dissolved in water (25 mL) and acetone (25 mL) at 40 oC,
followed by centrifugation. The extracted gelatin was then re-dissolved in 40 mL of an
acidic water solution (pH 2.5). Hydrophilic MUA-QDs (1.0 mL; 0.25 mg/mL) were
added to the gelatin mixture at this point. Acetone was added (drop wise) to the solution
to form NPs. After 30 min of stirring, 0.5 mL of glutaraldehyde solution (25% v/v) was
added as a cross-linker to stabilize the NPs. The particles were then purified and washed
using an ethanol and acetone mixture, and freeze-dried overnight.

Figure 3.1 Schematic illustration of preparation of QD-GNP1
52

3.2.5 Preparation of QDs-GNP2
Figure 3.2 shows the scheme of preparation of multilayer QDs-GNP2 by LBL deposition
method. LBL coating process starts from coating of two stabilized bi-layer of PSS and
PDAC at pH 6.0. In brief, a supporting film consisting of two PE bilayers by the alternate
adsorption of PSS solution (0.3 mg/mL in nanopure water, pH 6.0) and PDAC (0.3
mg/mL in nanopure water, pH 6.0) twice first covered the surface of as-prepared GNPs
(~200 mg). The polyanion PSS was deposited as the first layer on the positive GNPs.
After formation of two supporting bilayers, MUA-QDs (0.5 mg/mL in nanopure water,
pH 9.0) were deposited toward the PDAC layer, followed by the cycle of
PSS/PDAC/MUA-QDs adsorption. For adsorption of each layer, the suspending was
allowed for 15 min under vigorous shaking. Followed that, the particles were washed
with nanopure water and collected through centrifugation (5000 g for 5 min). The cycle
was run repeatedly until the formation of four layers of MUA-QDs on the GNPs. After
adsorption of the final MUA-QDs layer, the particles were protected by depositing a layer
of PSS. The multilayer NPs were then purified, freeze-dried and stored at 4 oC ready for
use.

Figure 3.2. Schematic illustration of preparation of QDs-GNPs by LBL technique.
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3.2.6 Characterization
Transmission electron microscopy (TEM) and scanning electron microscopy (SEM)
coupled with energy-dispersive X-ray spectroscope (EDX) were used to analyze the
morphology and composition of all the NPs. The TEM images were obtained using a
Philips CM-10 microscopy operating at 100 kV. A high resolution TEM (HRTEM, JEOL
2010 F, operating at 200 kV) was used to analyze the crystalline structure of MUA-QDs.
The SEM analysis was taken by a Hitachi 3400s SEM coupled with EDX. The average
diameter of the multiple layer NPs was calculated from TEM images by analyzing at least
200 NPs for each sample using ImageJ software (National Institutes of Health, USA).
The Zeta (ζ) potentials of the GNs with and without LBL coatings were measured by
Malvern Zetasizer 3000HSA, and calculated as the mean of five individual
measurements. The functional groups of nanomaterials were studied by using Fourier
transform infrared (FTIR) spectrophotometer (Bruker FTIR-IFS 55, Germany). UVvisible absorption spectra were recorded by UV-3600 spectrophotometer (Shimadzu,
Japan). PL spectra and quantum yields were measured by a QuantaMaster™ 40
Spectrofluorometer (Photon Technology International Inc., London, ON).

3.2.7 Analysis of pH effect in photostability
The pH effect on the PL stability of MUA-QDs and QDs-GNP2 were investigated further
under the excitation wavelength (λex) at 470 nm. Corresponding amounts of MUA-QDs
and QDs-GNs were suspended in distilled water with different pH values, i.e., 1, 4, 7, and
9, respectively. The pH value of the aqueous media was adjusted by using HCl and
NaOH. Each measurement was repeated at least three times.The light source is a pulsed
dye laser pumped by a pulsed nitrogen laser with the dye wavelength set at 480 nm (the
bandwidth of the dye laser output is about 0.04 nm). The emission was measured with a
monochromator set at 620 nm. Furthermore, there was a 550 nm long-pass filter used on
the emission side so that no excitation light can enter the detector, that is, the scattering
effect is ruled out. The PTI-patterned Strobe technique measures fluorescence decay
curves (i.e., fluorescence intensity as a function of time) directly. It is considered a faster
measurement than TCSPC (Time-Correlation Single Photon Counting) by using a
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nonlinear detection time scale to record the fluorescence intensity. The data analysis was
performed with Felix GX analytical software package using a 1-to-4 exponential fitting
function by χ2 minimization employing Marquardt−Levenberg algorithm with iterative
reconvolution. In order to carry our reconvolution, an instrument response function (IRF)
was measured by using a scattering suspension of Ludox in deionized water. The PL
decays required either a single or double-exponential function to fulfill fitting criteria,
such as the value and the randomness of residuals. For double exponential decays the
intensity-weighed average lifetimes were calculated using the following equation
(Equation 3.1) ,40
τave = ∑ ai τ2i / ∑ ai τi

(Equation 3.1)

where 𝑎𝑖 are the pre-exponential weights and 𝜏𝑖 the decay times obtained in the multi-

exponential fitting.

3.2.8 Cell viability/cytotoxicity study
The toxic effects of nanomaterials studied in this chapter on NIH/3T3 mouse cells
(ATCC) was tested by a commercial kit (MultiTox-Fluor cytotoxicity assay). The assay
was done following the manufacturer’s instruction. Briefly, 10,000 cells per well (of 96well) of the 3T3 cells were cultured in DMEM medium supplemented with 10% FBS at
37 °C, 5% CO2. After 24 hrs of culture, the medium was replaced with fresh medium
containing 5-fold serial diluted QDs-GNPs and MUA-QDs ranging from 25 mg/mL to
0.2 mg/mL, and from 6.25 mg/mL to 0.05 mg/mL, respectively. Cells without any
treatment were used as controls. After another 24 hrs, 20 μL of 2 X MultiTox-Fluor
multiplex cytotoxicity assay reagent was added to each well. An Omega microplate
reader (BMG Labtech, Ortenberg, Germany) at an excitation of 400 nm and an emission
of 505 nm was used in this study.

3.2.9 In vitro fluorescence imaging
NIH/3T3 mouse fibroblast cells (2 x 105 per petridish, glass bottom petridishes), were
cultured in DMEM medium supplemented with 10 % FBS at 37 °C, 5 % CO2, for 24 hrs.
The cells were then rinsed by PBS, and subsequently treated with DMEM mediums
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spiked with 0.1 mg/mL MUA-QDs, QDs-GNP2 and GNPs, respectively, and incubated
for 24 hrs. The treated cells were washed by PBS for three times and fixed using a PBS
solution containing 2.5% glutaraldehyde under for 30 min under mild shaking. After that,
the cells were washed for another three times by PBS and incubated with a PBS
mounting solution containing DAPI solution for 30 min. Afterwards the cells were
washed with PBS for another five times and were examined by a LSM Zeiss 510 Duo
Confocal microscopy.

3.3 Results and Discussion (I)
The initial work using QDs-GNP1 are presented and discussed in this section.

3.3.1 Characterization
The diameter of the MUA-QDs is estimated to be 5 ± 1 nm by TEM and HRTEM, as
shown in Figure 3.3a. The well-resolved lattice fringes on the HRTEM micrographs are
typical crystalline structures of CdSe QDs. Figure 3.3b shows spherical QDs-GNP1 with
average diameters of 150 ± 10 nm. In addition, TEM shows that free MUA-QDs are
generally not found outside GNPs.

Figure 3.3 TEM micrograph of MUA-CdSe QDs (a) and (b) QD-GNP1.
FTIR was then carried out to investigate the encapsulation of MUA-QDs in GNPs. Figure
3.4 shows FTIR spectra of MUA-QDs, GNPs and QDs-GNP1. C =O stretching can be
found in both GNPs and MUA occurring at ~1660 cm-1. GNPs in the FTIR spectrum
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show -NH bending between 1550 cm-1 and 1500 cm-1. Peaks at 1660 cm-1 are assigned to
the imide C–N group formed via a cross-linking reaction between gelatin and
glutaraldehyde, which is close to -C =O stretching. For MUA-QDs, previous studies have
shown that the carboxyl group of MUA may participate in the hydrogen-bonding
processes. The absorption band at 1200 cm-1 is attributed to the C–OH stretching of
MUA. The band at 1430 cm-1 can be found in both and is assigned to a combination of
the symmetric COO- stretching band of the carboxylate anion and the -CH2 scissors
deformation of the carboxylic acid.41 Unfortunately, they are quite weak, and could not
be identified in QDs-GNP1. Also, most of characteristic peaks of MUA-QDs (stretches of
–C=O, –CH2 and –OH groups) are observable in GNPs.

Figure 3.4 FTIR spectra of MUA-QDs, GNPs and QD-GNP1
A fluorospectrometer was then used to study the encapsulation of MUA-QDs in GNPs
(Figure 3.5). The maximum fluorescent emission peak (λem max) is found at 630 nm for
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MUA-QDs under an excitation wavelength (λex) of 460 nm. As expected, there is no
emission from the plain GNPs. There is a 24-nm red-shift in λem max while MUA-QDs
were encapsulated into GNPs. Previous reports indicate a blue-shift of λem max for the
gelatin encapsulating PbS QDs, which was claimed to be due to the polar environment of
gelatin on the dipole interaction of PbS QDs.24 However, it should be mentioned that the
PbS QDs used previously were synthesized by a hydrothermal method without the
protection of a stabilizer. In the other words, the surface of PbS QDs would be very
sensitive to environmental conditions. In our case, CdSe QDs were capped by long-chain
MUA molecules, which protect the surface atoms of QDs from direct interaction with
solution. The red-shift at the emission wavelength might be caused by extension of the
exciton wavefunction of CdSe QDs to the outer organic ligands. This results in a decrease
in the confinement energy of the exciton and the wavelength red-shift.39

Figure 3.5 Fluorescent spectra of MUA-QDs, GNPs and QD-GNP1
The QDs-GNP1 was further studied by using confocal laser scanning microscopy (Figure
3.6). The inset shows agglomerated NPs under the bright field. When the excitation, λex,
was 460 nm, a bright photoluminescenct signal could be captured from the NPs (green
dots in Figure 3.6). This further demonstrates that MUA-QDs can be successfully loaded
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into GNPs. No free MUA-QDs after the encapsulation are identified by confocal laser
scanning microscopy. It is noted that the isoelectric point (PI) for MUA is ~ 6, and the
acid pH (2.5) in the second desolvation may cause protonization of MUA-QDs, resulting
in slight aggregation. As shown in Figure 3.6, the photoluminescence was well
distributed around those QDs-GNP1; it seems that the possible slight aggregation did not
affect the homogenous encapsulation process. In addition, ~ 1 g of QDs-GNP1 could be
produced in each process. The amount of QDs incorporated inside of NPs can be
adjustable.

Figure 3.6 Confocal fluorescent of microscopy images of QD-GNP1. BF indicates
bright field and DF indicates the dark field, respectively.

3.3.2 Cytotoxicity
The cytotoxicity effects of the GNPs, CdSe QDs and QDs-GNP1 were studied using
NIH/3T3 mouse fibroblast cells. Cells were cultured to confluence. Different samples
were mixed with cells in medium and were continually cultured for 24 h. Figure 3.7
shows that MUA-QDs not encapsulated in GNPs have a significant adverse effect on cell
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viability when the concentration of MUA-QDs increases from 0.01 to 0.05 mg/mL.
Whereas GNPs and QDs-GNP1, at concentrations up to 5 mg/mL, are not toxic to cells.
In addition, no QDs released from GNPs have been found over a period of 5 days.
In sum, we initially used nature polymer gelatin as coating material for QDs to produce
luminescent NPs. The luminescent NPs, i.e. QDs-GNP1, exhibit good biocompatibility.
However, as we discussed above, the optimum pH ranges (2.5-4) for formation of GNPs
can cause aggregation of MUA-QDs, and may result in photobleaching. Further
improvement in photostability of gelatin-QDs system is required for its use in
bioimaging.

Figure 3.7 Cytotoxicity analysis of GNPs, MUA-QDs and QD-GNP1.

3.4 Results and Discussion (II)
This section presents the results for preparation of a new type of gelatin-QDs hybrid NPs
system

(i.e.

QDs-GNP2)

with

bight

luminescence,

biocompatibility for potential cell imaging use.
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photostability
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3.4.1 Materials characterization
The average diameter of the core-shell QDs-GNP2 is estimated at 484 ± 40 nm through
SEM and TEM results (Figure 3.8 a). TEM micrograph (Figure 3.8 b) clearly shows the
multiple layers of dense dark dots on the shell, which are attributed to the assembled
CdSe QDs verified by a high-resolution TEM. Element analysis carried by EDX (Figure
3.8 c) indicates the existing of elements S, Cd and Se on the layers, which are attributed
to the capping molecule MUA and two main compositions of the QDs.
The ζ potential of GNPs, MUA-QDs, and QDs-GNP2 are 24.1± 0.4 mV.−29.9 ± 0.48
mV, and−16 ± 0.4 mV, respectively.

The surface of the core
−shell QDs
-1

-GNP2 is

-1

negatively charged. Two specific bands located at 1020 cm and 1130 cm are found in
the FTIR spectra (Figure 3.9), which are assigned to the PSS characterization stretches
(Figure 3.9 b). The results indicate that the MUA-QDs have been successfully assembled
onto the GNPs with the assistance of PE layers. In addition, it is estimated that there are
0.25 mg QDs per 1 mg core-shell QDs-GNP2 (1:4 w/w) by comparing with the PL
intensities of QDs and QDs-GNP2 as mentioned in experimental section (Figure A1, see
appendix 1).
(a)

(b)

(c)

Figure 3.8. Characterization of QDs-GNP2 by electron microscopy.
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Figure 3.9. FTIR spectra of (i) bare GNPs, (ii) PE coating GNPs, (iii) single layer QDs
coating GNPs,(iv) multilayer QDs coating GNPs, and (v) free MUA-QDs.

3.4.2 Absorbance and PL spectra
Figure 3.10 displays the absorbance and PL emission spectra of MUA-QDs and QDsGNP2, respectively. It indicates that the first exciton absorption peak (λab) of MUA-QDs
is around 600 nm, and the maximum PL is occurred with the emission wavelength (λem)
at 617 nm. It is noted that a very slight blue shift (3 ± 1 nm) occurs to both λab and λem of
QDs-GNP2 as comparing to those of MUA-QDs. PL emission of small semiconductor
QDs are known to be dependent on either band-to-band recombination in the nanocrystal
core 30, 42 or radiative surface states.31-33 In our study, the blue-shift could be attributed to
the latter mechanism because PE matrix assisting the assembly of MUA-QDs layers may
offer a higher degree of surface passivation of charges via interacting with surface atoms
of QDs.31 Our results also indicate that the relative quantum yield (QY) of QDs-GNP2 is
1.8-fold higher than that of the free MUA-QDs. Thus, PE matrix may minimize the
surface nonradiative recombination and increase confinement of charge carrier, which
consequently cause higher band-gap energy, shorter wavelengths and higher quantum
yields (QY).31, 32
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Figure 3.10. (a) Absorbance and (b) PL spectra for MUA-QDs and corresponding QDsGNP2.

3.4.3 The pH effects on photostability
The photoquenching of luminescence at low pH value limits the application of QDs in
bio-imaging in vitro and in vivo,37, 42 for some important physiological cells normally live
in low pH values (<7), including endosomes and lysosomes inside cells (pH 5-6.5) and
some tumor cells (pH 6-6.9).43, 44 Here, we further studied the proton-resistant capability
of QDs-GNP2 in different pH values with the comparison of MUA-QDs. The weight
ratio of MUA-QDs to QDs-GNP2 is 1:4 to maintain the same amount of QDs in both
samples. Figure 3.11a shows that the PL intensity of MUA-QDs decreases with
decreasing of pH value from 9 to 1, whereas the PL intensity of QDs-GNP2 is relatively
stable, independent- pH value. It shows that the PL intensity of QDs-GNP2 is two times
higher than that of MUA-QDs at pH 1.0. The decreasing behavior of PL intensity could
result from the aggregation of free MUA-QDs at low pH, which could be caused by the
protonation of capping material MUA molecule. Agglomerations were observed in low
pH levels (data not shown).
In addition, the average lifetime (τave) of MUA-QDs and QDs-GNP2 as a function of pH
value (pH at 1, 4, 7, and 9) were measured using the TM-30 Laser Strobe time-resolved
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fluorometer, as shown in the Figure A1 (see appendix), in which the experimental data
are shown as dots, and numerical fits as lines.
As per equation 3.1, the calculated average lifetime (τave) of QDs-GNP2 is about 889 ±
23 ps, which is 3-fold longer than that of MUA-QDs (263 ± 10 ps) at pH 7.0. It is noted
that most reported lifetime for CdSe QDs is 3 to 20 ns. Our short calculated average
lifetimes of produced QDs could be related to the defects of the produced QDs caused by
oxidation. The PL decay of MUA-QDs is pH- dependent as shown in Figure 3.11b,
which is in agreement with previous reports.45 The average lifetime (τave) for free MUAQDs decreases dramatically from 285 ps to 112 ps with decreasing pH value from 9.0 to
1.0. In contrast, the τave of QDs-GNP2 (775 ps ~ 914 ps) does not change significantly
along with the change of pH value from 9 to 1. Acid etching results in the changes of
nanocrystal semiconductive structures, and lead to the decreases of the PL intensity and
lifetime of QDs.31
Here, the negatively changed PSS layer may neutralize the surrounding protons in acidic
conditions, and, therefore, against the potential proton effect on the PL photostability of
the core-shell QDs-GNP2. In addition, the immobilization of QDs on GNP2 prevents
QDs with negative changes from aggregations caused by the addition of protons. As a
result, the PL signals of QDs-GNP2 are relatively stable in a broad range of pH value
from 9 to 1.

Figure 3.11. The pH effects on (a) PL intensity and (b) average lifetimes
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3.4.4 Cytotoxicity analysis of QDs-GNP2
We further investigated the cytotoxicity of the QDs-GNP2 with the comparison of MUAQDs. NIH/3T3 mouse fibroblast cell line was treated by free MUA-QDs and QDs-GNP2
with weight ratio of 1 to 4 to maintain the same amount of QDs in both samples.
MultiTox-Fluor assay was used to analyze the cell viability. When the concentration of
QDs-GNP2 increases from 5 mg/mL to 0.2 mg/mL, the relative cell viability (%)
increases up to 140% as compared to the control samples (Figure 3.12). It is noted that
GNPs may enhance the cell proliferation.46 As indicated by above result (Figure 3.6), no
significant toxic effect was imposed on cells when the concentration of GNP2 is up to 5
mg/mL. Whereas the relative cell viability (%) decreases from 100% to 82% when the
concentration of MUA-QDs increases from 0.05 mg/mL to 1.25 mg/mL. With further
increasing concentration of MUA-QDs up to 6.25 mg/mL, the cell viability dramatically
decreases to 20%. Meanwhile, the relative cell viability percentage dramatically drops to
50% when the concentration of QDs-GNP2 increases up to 25 mg/mL, which might be
related to the negative interference of florescent detection caused by the high
concentration of non-transparent QDs-GNP2.

Figure 3.12. Cytotoxicity profile of MUA-QDs and corresponding QDs-GNP2 after 24
hrs incubation with 3T3 cells. Percent viability is expressed relative to control cells (n=3)
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3.4.5 In vitro bio-imaging application
We subsequently investigated the core shell QDs-GNP2 in vitro bio-imaging applications
by using confocal microscopy. The NIH/3T3 mouse fibroblast cell line was applied and
incubated with 0.1 mg/mL MUA-QDs and 0.4 mg/mL QDs-GNP2 for 24 hrs,
respectively. Figure 3.13a indicates that the cells are alive with mixing GNPs (0.3
mg/mL). As shown in Figure 3.13b, MUA-QDs are observed on the surface of most of
cells (red color), which is in agreement with previous reports.8 Very few MUA-QDs are
suspended in the culture media. The nonspecific cellular uptake of MUA-QDs results
from passive endocytosis due to its very small particle size.8,

47-49

In addition, the

produced QDs-GNP2 with high photostability (red color) are preferred to attach on the
surface of the cells (Figure 3.13c). It is unlikely that NIH/3T3 mouse fibroblast cells
could naturally uptake of large QDs-GNP2 with average diameter of 480 ± 40 nm. The
internalization of NPs with such a large diameter through passive endocytosis could
merely be possible to specialized mammalian cells (such as monocytes, macrophages and
neutrophils) via phagocytosis.50 Previous reports indicate that the negatively charged
surfaces (PSS dominated) are favorable to cell adhesion and spreading.51 In addition, the
advantage of using PSS as an out layer may lead to longer circulation time in vivo. 52

Figure 3.13 Confocal microscopy images of (a) GNPs (0.3 mg/mL), (b) MUA-QDs (0.1
mg/mL), and (c) QDs-GNP2 (0.4 mg/mL) after co-incubation with NIH/3T3 mouse
fibroblast cells. All nucleuses were labeled with DAPI (blue).
Consequently, our biocompatible and fluorescent QDs-GNP2 are favorable to attach onto
the cell surface, and can be used as an alternative fluorescent imaging agent for cell
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labeling, especially in acidic conditions. It is also noted that the QDs-GNP2 interact with
cells through the electrostatic interaction (nonspecific interaction). Further efforts will be
taken to modify the surface of the hybrid nanospheres for targeted cell

3.5 Conclusions and Prospects
In conclusion, we have prepared two different biocompatible quantum dots-GNPs
systems (QD-GNPs) for bioimaging application. The first system involves utilizing
gelatin for directly embedding quantum dots (QD-GNP1) to form a quantum
dots/gelatine core/shell structure. TEM result show QD-GNP1 has an average diameter of
200 nm with QD embedded. QD-GNP1 exhibits bright fluorescence with maximum
emission wavelength at 613 nm. The results from cytotoxicity test indicate good
biocompatibility of QD-GNP1. To improve photostability of QD-GNPs system, we
further prepared a new system consist of a QDs embedded polyelectrolytes (PE) shell
coated gelatin nanoparticles (QD-GNP2) through a LBL process. Electronic microscopy
results show the QD-GNP2 has a gelatin core and PE shell, with an averaged diameter of
~480 nm. Four layers of CdSe QDs were showed embedded in the PE shell. The
nanocomposites exhibit good dispersibility and extremely bright and stable PL property
in aqueous solution under a wide pH range. The quantum yield and lifetime of
encapsulated QDs are found improved due to the multilayer PE protection. Good
biocompatibility of the as-prepared NPs is further demonstrated by cytotoxicity study.
The bright PL allows the NPs for detecting and labeling living 3T3 cells, which indicates
the QDs-GNPs system could be a suitable candidate for bio-imaging application. We
believe that our QDs-GNPs systems could be used for in situ real-time
monitoring/imaging drug delivery in future.
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CHAPTER 4
DEVELOPMENT OF BIOCONJUGATED MAGNETIC
LUMINESCENT NANOMATERIALS FOR BACTERIAL
CAPTURE, DETECTION AND ANTIBACTERIAL
APPLICATIONS

4.1 Introduction
Bacteria can lead to serious infectious diseases and environmental contamination, and
bring a huge public health burden.1 In particular, gram-negative bacterium Escherichia
coli and gram-positive bacterium Staphylococcus aureus are known as two of the leading
causes in food borne diseases in the world.2, 3 In addition, bacterial infections are also
found in the skin, soft-tissue, bone, joint, and endovascular disorders.4, 5 Antibiotics have
been developed to treat bacterial infections, but the effective dosage is not well
controlled. In addition, the unique cell wall made of highly cross-linked peptidoglycan
offer a rigid shell to protect the gram-positive bacteria from osmotic pressure, external
hazard macromolecules permeability and antibacterial enzyme digesting, which make the
treatment of their infections with much difficulty.6 Laboratory diagnosis of bacterial
infectious disease depends mainly on techniques such as cell culture, enzyme-linked
immunosorbent assay (ELISA) and polymerase chain reaction (PCR) , while they are
normally time-consuming and involved with multiple steps that affect the assay
efficiency.7, 8 In addition, very few bacterial cells may cause disease as they can double
their population less than 20 min.9 Therefore, rapid capture, detection, and
decontamination of bacteria are strongly demanded to avoid or minimize contamination
of the environment, food, and infections.
In recent, engineered magnetic nanoparticles (MNPs) conjugated with biomolecules have
shown promises in applications in drug delivery, magnetic separation,10, 11 sensor, celltracking,12 and bio-imaging,13, 14 because of their inducible magnetization, tunable size,
nontoxic and biodegradable. Bio-molecules, such as antibody,15 antibiotics,16-19
carbohydrate,20 and small organic molecules,21 have been reported to conjugate MNPs for
bacterial labelling and detection. In particular, bio-conjugated antibiotics to nanostructure
can offer a novel manner to simultaneously separate and kill the bacteria from
contaminated source at the early stage. For example, Xu and co-workers conjugated FePtbased magnetic NPs with vancomycin, and through peptide binding captured E. coli at a
low concentration of 3 x 104 cells/mL.16, 17, 19 El-Boubbou et. al. conjugated lectin to
MNPs and used mannose to bind, capture and kill.E. coli 20
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To improve the efficiency and versatility of nanoparticles (NPs) in numerous
applications, multiple functionalities have been incorporated to form hybrid MNPs. In
particular, optical properties such as fluorescence allow sensitive and quantitative
detection of bacteria 22 and visualization of cell structure.23 Thereby, it is of advantage to
develop of fluorescent magnetic nanoparticles (FMNPs) that posse both fluorescent and
magnetic properties, regard to detection, imaging and cell tracking. Typically, FMNPs
include a core–shell structure, i.e. a magnetic core coated with a fluorescent shell. The
fluorescent shell can be composed of polymers and inorganic materials loaded with
organic dye,24-26 quantum dots,27 or other complexes.28, 29 Silica is one of the well-studied
materials that can act as a shell due to its functional surface, and its unique porous
nature.30-32 Previous studies demonstrated that fluorophore-loaded mesoporous SiO2 NPs
are 20 times brighter than semiconductor quantum dots.33, 34 They can be taken up by
dendritic cells for cell tracking and cancer treatment.35, 36 The magnetic cores of most
FMNPs are intended to be Fe2O3-rich materials.37 However, compared to hematite
(Fe2O3) and other magnetic materials, magnetite (Fe3O4) shows higher magnetization,
about 65 emu/g 32, 38 and has various applications in biosensing and imaging.39, 40
The common method for preparation of silica coated iron oxide nanoparticles (SMNPs)
involves two steps, i.e. synthesis of iron oxide nanoparticles (IONPs) and post coating of
silica on the surface. Several methods have been developed to synthesize IONPs,
including co-precipitation, hydrothermal and thermal decomposition method. Coprecipitation process is one of the most preferred ways to produce magnetite and
maghemite, which involves co-precipitation of Fe2+ and Fe3+ in aqueous solution by
addition of base. The reaction runs under mild condition (room temperature) and the
products are hydrophilic and ready for further silanation. However, the drawbacks are
poor crystalline of the particles and difficulty in controlling of the size distribution. The
other two approaches, in particular thermal decomposition method, require high
temperature and thus can produce particles in good crystalline structure and narrow size
distribution. However, the NPs are usually coated by hydrophobic ligands for thermal
decomposition method. Thus additional surface modification such as ligand exchange to
bring NPs into aqueous solution is required prior for further coating with silica shell. For
silica coating, there are two widely used methods. The first one is based on the Stöber
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process,41 which comprises the hydrolysis and condensation of a sol-gel precursor such as
TEOS. In the second method, silica shell is produced via the microemulsion process,
where reverse micelles are use to confine and control the condensation of TEOS.42 In
both methods, fluorescent dyes can be conjugated to silane (such as APTS) before
condensation of TEOS, to form fluorescent shell.
Alternative strategy for preparation of FMNPs is one-pot synthesis scheme. In our group,
we previous developed a one-pot synthesis to produce dye labeling silica-coated
magnetite NPs. The process simplifies the reaction by co-precipitation of iron salt
directly in an oil-water micelle, followed by condensation of TEOS on the IONPs surface
in the same solution. Improved fluorescent properties and magnetic properties have been
reported.
In this chapter, we reported preparation of a new bioconjugation of FMNPs with
antibiotic gentamicin for ubiquitous capture, detection and decontamination of bacteria
applications. We introduced and compared two approaches in preparation the FMNPs,
i.e. one-pot co-precipitation way and two-step decomposition method. The as-made NPs
are thus named FMNP1 and FMNP2, respectively. In addition, gentamicin (Gm) is a
FDA approved thermal-resistant antibiotic for the treatment of infection caused by gramnegative bacteria and susceptible gram-positive bacteria. The amino groups of Gm show
positive charges through protonation in physiologic solutions, which contribute to the
interaction of Gm with lipopolysaccharides (LPS) on the surface of Gram-negative
bacteria and phospholipids and teichoic acid on the surface of Gram-positive bacteria,
respectively.43, 44 We thoroughly investigate the interaction between bacteria and FMNPs
with/without Gm-bioconjugation. Meanwhile, the detection sensitivity and toxic effect
are also investigated.

4.2 Experimental
Unless otherwise stated, chemicals were obtained from Sigma-Aldrich.
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The scheme in Figure 4.1 illustrates the preparation and bio-conjugation of FMNPs for
bacterial capture. The experimental details are described below.

Figure 4.1 Schematic illustration of the synthesis of FMNPs used for E. coli capture and
magnetic separation in solution

4.2.1 Preparation of FMNP1 by one-pot method
The FMNP1 were produced by an one-pot reaction involving a process of base-catalyzed
precipitation of Fe2+/Fe3+, followed by the condensation of tetraethylorthosilicate (TEOS,
99%), and the in situ encapsulation of fluorescein isothiocyanate (FITC, 90%) in the shell
as shown in Figure 4.1. Briefly, 7.3 g of cetyl-trimethylammonium bromide (CTAB)
(98%) was added to 100 mL of toluene (99.8%). The mixture was stirred at 600 rpm for 4
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h, followed by the slow addition of an aqueous solution of FeCl2/FeCl3 (0.22 g/0.56 g, 7.3
mL; FeCl2, 98%, FeCl3, 97%). The mixture (solution A) was stirred vigorously for 8 h.
Then, 1 mL NH4OH solution (28%) was added drop-wise to the solution. Solution A was
stirred for another 4 h. Meanwhile, 5.5 mg fluorescein isothiocyanate (FITC) and 25 µL
aminopropyltriethoxysilane

(APTS,

98%)

were

mixed

to

form

N-1-(3-

triethoxysilylpropyl)-N’-fluoresceyl thiourea (FITC-APTS). After 2 h, 2.5 mL of TEOS
was added to the FITC-APTS solution. This mixture (solution B) was stirred
continuously for an additional 3 h using aluminum foil to protect the dye conjugate from
light. Solution B was then added drop-wise to the main reaction of the solution A pot and
continuously stirred for 5 days. All reactions were kept under N2 atmosphere. Aluminum
foil was used to cover the reactor to protect the products from photo-degradation. Finally,
the reaction was stopped by addition of 20 mL ethanol. The particles were washed with a
mixture of ethanol/acetone (1:1, v/v) and purified by repeat centrifugation. The as-made
FMNP1 were then freeze-dried and stored in the dark.

4.2.2 Preparation of FMNP2 by two-step coating method
The FMNP2 were prepared by a two-step process. Firstly, monodisperse IONPs were
synthesized through a modified thermal decomposition method.45 In brief, 1.32 g of
FeCl3 and 7.4 g of sodium oleate (TCI, 95%) were dissolved in a mixture of 16.3 mL of
absolute ethanol, 13.08 mL of water and 28.5 mL of hexane (95%). The solution was
refluxed at 60 ºC for 4 h, followed by washing with a solution of ethanol and water (1:1,
v/v) five times. The resultant iron-oleate precursor was then dried under vacuum
overnight at 70 °C. Afterwards, 1 g of wax-like precursor was re-dissolved in a solution
of 177.3 μL oleic acid (99%) and 7.1 mL triethylamine (98%). The solution was stirred
vigorously and heated to 360 °C rapidly under argon atmosphere, and then aged for 1 h.
After that the solution was cooled down, washed with hexane and ethanol (1:3, v/v)
mixture and purified by centrifugation for three times. The particles were finally
dissolved in chloroform and kept at room temperature.
Silica coating of IONPs were carried out through a modified sol-gel method.46 Firstly, 1
mg of fluorescein isothiocyanate was dissolved in 0.5 mL of absolute ethanol, followed
by addition of 10 µL of APTS. The solution was stirred for 2 h. In another vessel, 50 mg
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of IONPs were mixed in 20 ml of an aqueous solution of 2% CTAB. The mixture was
stirred vigorously and heated to 70 °C to boil off chloroform. The NPs mixture was
further filtered through a 0.45 μm syringe filter to remove large aggregates. Next, 5 mL
of the filtered mixture was added into a solution of 43 mL water and 350 μL NaOH (2 M)
and heated to 70°C. The mixture of 0.5 mL of TEOS and 10 μL of APTES-FITC solution
was then slowly added to the CTAB aqueous solution. After 15 min, 127 μL of
trihydroxysilylpropylmethylphosphonate (THPMP) (42%) was added to the solution and
stirred for another 2 h under dark. Then, the as-synthesized FMNP2 were precipitated by
adding excess methanol and collected by centrifugation. To remove CTAB, the FMNP2
were further re-dispersed and heated at 60 °C for 15 min in a solution containing 160 mg
NH4NO3 and 60 mL 95% ethanol. Afterwards, the NPs were purified by by repeating
centrifugation and washing with ethanol. Finally, the FMNP2 were freeze-dried overnight
and kept under dark ready for use.

4.2.3 Bioconjugation of FMNPs with Gm
For bioconjugation of Gm, both FMNP1 and FMNP2 at 2.5 mg/mL in water were reacted
with a glutaraldehyde solution (Glu, Grade I, a final concentration of 3% in water)
overnight in the dark, respectively. The mixture was then purified by centrifugation (5800
rpm for 5 min) to remove the supernatant, and further re-suspended in water. The
purification process was repeated twice, and the Glu conjugated FMNPs were then
freeze-dried. To immobilize Gm onto the surface of the FMNPs, a solution containing
gentamicin sulfate (1 mg/mL) and 2.5 mg/mL FMNPs was mixed and stirred overnight
under dark. The unbound Gm was removed by repeated centrifugation and washing, as
described above. The solution was then mixed with 1% bovine serum albumin (BSA,
96%) solution for 1 h to block free formyl group onto the surface of the FMNPs. Finally,
the purified Gm-FMNPs were freeze-dried and stored in the dark at 4 °C. In addition to
the negative control samples of bare FMNPs and Glu-FMNPs, another negative control
sample used to evaluate the Gm-bioconjugation was ethanolamine (EA, 98%). The
conjugation of EA to FMNPs followed with the same procedure described above.
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4.2.4 Characterization
The morphology of NPs and their interaction with bacteria was examined by TEM and
TEM-energy dispersive X-ray spectrometry (TEM/EDX). The TEM images were
obtained using a Philips CM-10 microscope operating at 80 kV. The magnetic properties
of both IONPs and MNPs were measured by Vibrating Sample Magnetometer 7404
(VSM, Lakeshore Inc.). The hysteresis loop was measured at room temperature under 1
kOe (1 T). A superconducting quantum interference device (SQUID, Quantum Design)
was used for measuring of blocking temperature of FMNPs. The zero-field-cooled (ZFC)
and field-cooled (FC) magnetization curves of the FMNPs were recorded at 50 Oe over a
temperature range of 5 to 300 K. The sample capsule was diamagnetic and did not
contribute to the measured result.
The Fe K-edge X-ray absorption near edge structure spectroscopy (XANES) study was
conducted to investigate the composition of NPs by using the Soft X-ray
Microcharacterization Beamline (SXRMB) at the Canadian Light Source (CLS). The
specimens were placed on the sample manipulator in a vacuum chamber (~10-8 Torr).
XANES were collected in Total Electron Yield (TEY) by measuring the specimen current
in the presence of a voltage bias. In addition, the XANES spectra have been normalized
to I0, the intensity of the incoming photon beam.
Fluorescence microscopy (Zeiss Axio Imager Z1) analysis was conducted to study the
interaction between the bacterial cells and FMNP1 with and without Gm bioconjugation
by placing glass slides of the samples under an excitation wavelength (λex) of 492 nm. In
addition, the fluorescent emission signals of the FMNP1 were detected by
fluorophotometry (QuantaMsterTM 30, PTI) with an excitation wavelength (λex) of 492
nm. Fourier transform infrared (FTIR) transmittance spectrometry was carried out to
identify the Gm bioconjugation. A Bruker Vector 22 was used in the range of 600–4500
cm-1 with a resolution of 4 cm-1 and 64 scans.

4.2.5 Bacteria Capture
In a typical experiment, bacteria E. coli (K-12, sub-strain W3110) and S. aureus (ATCC
33807) were grown at 37 °C for 24 h in broth media, respectively. The optical density
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(O.D.) of this culture was adjusted to having a concentration of approximately 1 x 107
CFU/mL. The cells were harvested by centrifugation (8000 rpm, 5 min) and further resuspended in phosphate buffered saline (PBS, 0.01 M, pH 7.4) buffer containing GmFMNPs (final concentration of 0.1 mg/mL). The mixtures were further incubated for 20
and 60 min, respectively. Two samples with different interaction times (t) were separated
from the solution using magnetic confinement. Both samples were washed three times,
and then re-suspended in PBS for TEM analysis. The mixture was then applied in an
external magnetic field (0.2 T) for 1 min. After washing twice, the magnetic confined
complex was re-suspended with PBS.

4.2.6 Analysis of the antibacterial effect
The antibacterial property of Gm-FMNP1 to E. coli was analyzed by using plate counting
technique. Typically, 200 µL of the above bacterial solution and NPs mixture were
spread homogeneously onto agar plates. All the agar plates were then incubated overnight
at 37 °C. The number of CFU of the bacteria was calculated following the incubation.
The antimicrobial efficiency of Gm-FMNPs to E coli was further investigated by
standard agar disc diffusion. Briefly, one isolated E. coli colony was incubated overnight
in fresh broth at room temperature to reach a bacterial culture of ~107 CFU/mL. A 200
µL aliquot of this culture (~105 CFU/mL) was spread onto agar plates. Sterile filter paper
discs (7 mm) immersed in 1 mL PBS containing different standard concentrations of free
Gm and FMNP1 solution samples (both conjugated with or without Gm) were then
applied to the plates and incubated for 18 h at 37 °C. The antibacterial efficiency of the
Gm-FMNPs was then determined as a function of E. coli colony inhibition diameters
based on the calibration exponential curve obtained in experiments with known
concentrations of the standard solutions.

4.2.7 Determine the concentration of gentamicin on the FMNP1
The amount of gentamicin conjugated on the GM-FMNPs was determined via an ophthalaldehyde assay reported by C. Lecároz with slight modification.47 In brief, the ophthalaldehyde reagent was formulated by adding 25 mg of o-phthalaldehyde, 625 µL of
methanol and 30 µL of mercaptoethanol to 5.6 mL of sodium borate (0.04 M, pH 9.7)
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under dark for at least 24 h at room temperature. This reagent should be used in 48 h.
Standard concentrations of gentamicin sulfate were prepared by serial dilution with
borate buffer at concentrations of 50, 25, 12.5, 6.25, 3.1, and 1.5 µg/mL. The
concentrations of gentamicin in the GM-FMNPs were measured by spiking the NPs in
the borate buffer (1 mg/mL). Then, o-phthalaldehyde reagent, gentamicin solutions
(standard solutions and NPs solutions), and isopropanol were mixed in similar
proportions and stored for 30 min at room temperature. The amount of gentamicin was
evaluated by measuring the adsorptions at 292 nm (Shimadzu 3600 UV-visible
spectrophotometer) to obtain a standard adsorption curve relating to gentamicin
concentration. The concentrations of gentamicin in the NPs solution were calculated by
means of the standard curve.

4.2.8 Preparation of thin section samples for TEM analysis
In the initial experiment, thin section treated samples were prepared for TEM/EDX to
confirm the interaction of Gm-FMNP1 with bacteria E. coli. The samples were prepared
by fixing the above bacteria-NPs complex (E. coli incubated with and without GmFMNPs for 20 min and 60 min, respectively) with 2.5% (v%) glutaraldehyde in sodium
cacodylate buffer (0.1 M, pH 7.4). After 2.5 h fixation, the cells were washed three times
in cacodylate buffer with centrifugation (~ 4500 g for 6 min), and further fixed with 1%
osmium tetroxide in a cacodylate buffer solution for 1 h. The samples were washed again,
and the final pellets were placed in drops of 5% Noble agar. The samples were further
fixed in 2% uranyl acetate for 2 h, followed by dehydration in an ethanol solution with
ascending gradients of strength (50%, 70%, 85%, 95% with two changes in absolute
ethanol, 15 min each). The specimens were then washed in propylene oxide twice and
infiltrated with an EPON resin: propylene oxide mixture (ratio 1: 1 and 3: 1, placed in
each once) and twice in pure EPON resin. Sample resin blocks were prepared by
embedding the samples in resin and polymerizing them at 60 °C for 2 days. The resin
blocks were then trimmed and sectioned (80–100 nm) on a Reichert Om-U3
ultramicrotome with a diamond knife. Ultrathin sections were placed on 200-mesh
formvar/carbon-coated nickel (Ni) grids for further TEM/EDX analysis.

81

4.3 Results and Discussion
4.3.1 Characterization
The morphology of both FMNPs was characterized by TEM as shown in Figure 4.2. An
obvious boundary between the core and the shell is observed in most of the particles. For
FMNP1, the average diameter of the iron oxide core is estimated to be 50 ± 8 nm, while
the thickness of the silica shell is estimated to be 12 ± 5 nm (Figure 4.2a). The mean
particle size is approximately 65 ± 8 nm.

For FMNP2, the average diameter of

monodispersed IONPs is 18 ± 2 nm (Figure 4.2b). The average diameter of the core-shell
FMNP2 is about 30 ± 5 nm, and the shell is estimated at 5 ± 2 nm.
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Figure 4.2 TEM micrograph of the core–shell structures of FMNP1 (a) and FMNP2 (b).
The core-shell structured both FMNPs was further investigated through the XRD. As
shown in Figure 4.3, the typical peak of semi-crystalline SiO2 is broad and can be found
around 23° (2 θ). The other positions (labelled) and intensity of the peaks are coincident
with XRD pattern for bulk Fe3O4 or α-Fe2O3 phase with cubic inverse spinel structure
(JCPDS file 39-1346 and 190629, respectively). Thus, combining the TEM images, the
semi-crystalline SiO2 shell has a lighter color in the TEM micrograph, whereas the Fe3O4
or α-Fe2O3 core has higher electron density, and therefore, has a darker color. For
FMNP2, we also examine the oxidation status of FMNP2 by XANES. The results show
the Fe K-edge in the XANES spectra of the standard Fe3O4 sample and FMNPs (Figure
A3, from Appendix 3). The Fe K-edge excitation threshold (E0) is the maximum of the
first derivative of the XANES spectra. Clearly, the FMNPs have the same E0 as that of
Fe3O4. Thus, the core of the FMNPs is attributed to Fe3O4.
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Figure 4.3 XRD profiles of the core-shell structured (a) FMNP1 and (b) FMNP2
Magnetite (Fe3O4) NPs are known for their unique superparamagnetic property at room
temperature 48. As shown in Figure 4.4, typical hysteretic loops for superparamagnet are
found for both FMNPs by VSM analysis, which indicate both particles exhibit
superparamagnetic property. Our calculation shows the saturation magnetization (Ms) at
room temperature of FMNP1 and FMNP2 are 2.512 emu/g and 1.5955 emu/g,
respectively. In comparison with other Fe-based magnetic materials, Fe3O4 has high
thermal stability with a high Curie temperature (Tc) of 858 K. Figure 4.4 shows the
superparamagnetic behavior of the FMNPs during field cooling (FC) and zero-field
cooling (ZFC) from SQUID analysis. The results indicate the blocking temperatures of
FMNP1 and FMNP2 are at 120 K and 115 K, respectively.
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Figure 4.4 Characterization of magnetic property. VSM measurement of hysteresis loops
of FMNP1 (a) and FMNP2 (b); SQUID analysis of zero-field-cooled (ZFC)
magnetization curve of FMNP1 (c) and FMNP2 (d) at 50 Oe.
Fourier Transform Infrared Spectroscopy (FTIR) was further carried out to confirm the
formation of silica shell and bioconjugation of Gm to FMNP1. As shown in Figure 4.5,
Si-O-Si stretch is found at 1070 cm-1. Furthermore, the typical –CH2 stretch at 2930 cm-1,
the –C=N stretch of the imine group, and –C=N–R at 1640 cm-1 appears in the spectrum
of Gm-FMNP1. No –C=O stretch at 1760 cm- is found after Glu linking the FMNPs and
Gm. Similar results were also found for Gm-FMNP2 (data not shown).

85

Figure 4.5 FTIR absorption spectra of FMNP1, glutaraldehyde (Glu) modified FMNP1
(Glu-FMNP1), and Gm-FMNP.

4.3.2 Capture, detection and decontamination of E. coli by GmFMNP1
It should be noted that, in our initial experiment, Gm-FMNP1 was prepared for capturing
bacteria E. coli. As shown in Figure 4.6, Gm-FMNP1 (1 mg) are found to capture and
remove E. coli cells (1 x 107 CFU/mL) under an external magnetic field of 0.2 T.
Specifically, approximately 90% of the Gm-FMNP1 can be separated from the solution
within 6 min, and almost no E. coli cell is found in the suspension after 20 min of
magnetic confinement.

Figure 4.6 Magnetic capture of bacterium E. coli under external magnetic field.
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We further used fluorometer and fluorescent microscopy to confirm the capability of GmFMNP1 for bacteria capture. For Gm-FMNP1, the maximum fluorescent emission (λem)
measured by a fluorometer is at 517 nm with an excitation wavelength of 492 nm, while
free FITC with λem = 513 is shown in Figure 4.7a. After mixing with E. coli cells for 20
min (1 x 103 CFU/mL), a broad emission peak with a substantial decrease in intensity is
observed for Gm- FMNPs. It is also found that the peak has a slight red-shift to λem at 528
nm. No significant change is observed over time. This decreasing in fluorescent intensity
and red shift could be attributed to formation of aggregation between NPs and bacterial
cells, which cause inner filter effect to suppress the blue side of emission spectrum by reabsorption of photons.49 Through fluorescent microscopy, we can further confirm the
formation of aggregation. Figure 4.7b-2 shows clearly that E. coli cells attached to GmFMNPs are aggregated in solution, while there is no aggregation when the E. coli were
incubated with FMNPs alone (Figure 4.7b-1). Therefore, it clearly shows that Gmconjugated with FMNPs are able to recognize very low concentrations of E. coli.
We then used TEM to study the capability of Gm-FMNP1 to capture E. coli. FMNP1
without Gm were used as the negative controls, including FMNP1, glutaraldehyde (Glu)FMNP1, and ethanolamine (EA)-FMNP1. From Figure 4.8, we found that the bacterial
cells were attached with the aggregation of dark dots in the mixture of Gm-FMNP1 and
E. coli. It is interesting that instead of the central cylindrical region of the cell, the cell
poles (dark hemispheres) are more aggressively attacked by Gm-FMNP1. No interaction
between E. coli cells and the negative control samples was found (Figure 4.8). TEMEDX analysis of thin section samples (Figure 4.8e) clearly shows that the dark dots
interacting with E. coli contain iron (Fe) from the core of the FMNP1 and silicon (Si)
from the mesoporous silica shell. The peaks of nickel (Ni) stem from the TEM sample
grid. Thus, these dark dots are attributed to FMNP1 (Figure 4.8 d). It is believed Gm has
strong interaction with lipopolysaccharides on the Gram-negative bacterial cell wall,50, 51
while EA is inert towards E. coli. We can conclude that Gm-FMNP1 can recognize and
attach with the surface of E. coli cell because of the linkage of Gm to E. coli cell surface.
This attachment mediates the capturing of bacterial cells.
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Figure 4.7 (a) Fluorescent spectra of free FITC, FMNP1, and the Gm-FMNP1
before/after detecting E. coli cells (1x103 CFU/mL); (b1) FMNP1 mixing with E. coli,
1x103 CFU/mL, (with dark field (DF, left) and bright field (BF, right); (b2) E. coli
interacting with Gm-FMNP1 with dark field (DF, left) and bright field (BF, right) when t
= 20 min.
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To further investigate the interaction between Gm-FMNP1 and E. coli, we measured the
samples of bacteria and NPs which were cultured for 20 min and 60 min as shown in
Figure 4.8b and c, respectively. The interaction between Gm-FMNP1 and E. coli cells is
observed (indicated by a blue arrow) when the interaction time (t) is 20 min, maintaining
the integral ‘‘envelope’’ structure. However, the areas of the cell wall to which the GmFMNP1 attach exhibit texture changes (see the small insert in Figure 4.8b). Significant
disruption of the membrane and cell lysis occur with an increase in the interaction time
from 20 to 60 min. Figure 4.7c shows that the bacterial cell membranes are broken and
the cytoplasmic matrix appears to be leaking out. Such phenomena are not observed in
samples of bacteria mixed with negative control samples, i.e. FMNP1 (Figure 4.8a), GluFMNP1, and EA-FMNP1, respectively. Furthermore, no bacterial cells with an integral
structure are observed using TEM when the sample was incubated for 3 h. Previous
report indicated that the polycationic from gentamicin could induce strong cell walladsorption at an early stage.51 After that, cationic Gm may rearrange the
lipopolysaccharide packing order through ionic bonding, consequently disrupting
bacteria’s outer membrane and promoting membrane permeability.52,

53

Thus, in our

study, it is likely that the Gm- FMNP1 attach and damage the cell wall first, and are then
adsorbed within the cell.
The response of E. coli to the Gm-FMNP1 was further studied by calculating the colonyforming units (CFU) of both supernatants and precipitates. A cultured E. coli sample was
used as a positive control. Negative controls are FMNP1 without Gm, i.e. FMNP1, GluFMNP1, EA-FMNP1. Diluted E. coli cells were incubated with Gm-FMNP1 and
negative controls for 30 min, respectively. We found no significant precipitation is
observed in the E. coli suspensions mixed with negative controls: FMNP1s, Glu-FMNP1,
and EA-FMNP1, respectively. However, obvious precipitation can be found in the E. coli
suspension mixed with Gm-FMNP1. To evaluate the antibacterial activity of GmFMNP1, all samples were washed and freeze-dried several times to remove free Gm from
the sample.
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Figure 4.8 Analysis of the interaction between NPs and bacterium E. coli. (a), TEM
image of E. coli mixing with FMNP1 without Gm conjugation. (b) E. coli mixing with
Gm-FMNP1 with less than 20 min of interaction time (t). (c) E. coli interacting with GmFMNP1 when t = 60 min. (d) Thin section TEM analysis of E. coli mixing with GmFMNP1 when t = 20 min. (e) The TEM-EDX spectrum of the Gm-FMNP1. (f) Thin
section TEM analysis of E. coli mixing with Gm-FMNP1 when t = 60 min.
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Figure 4.9 shows photographs of the resulting colonies in agar plates for all samples. The
cultured E. coli mixed with FMNP1 (Figure 4.9a-A2), Glu-FMNP1 (Figure 4.9a-A3), and
EA-FMNP1 (Figure 4.9a- A4), respectively, show a similar result with the positive
control (Figure 4.9a-A1); whereas Gm-FMNP1 (0.1 mg) significantly inhibit the growth
of E. coli. No living cells can be found throughout the suspension of E. coli mixed with
Gm-FMNP1 as shown in (Figure 4.9a-A5 and -A6). Further analysis indicates that the
bacterial concentration of those FMNP1 without Gm is 0.8 x 103 CFU/mL, which is
similar to the positive control (1.0 x 103 CFU/mL). However, the bacterial concentration
decreases dramatically in the sample of Gm-FMNP1 as shown in Figure 4.9b. The results
confirm that Gm-conjugation is playing the key role to allow the FMNP1 to interact with
E. coli. The antimicrobial susceptibility of E. coli to Gm-FMNP1 was further determined
by the agar disk diffusion method with the comparison of the calibration curve obtained
by testing pure Gm (Figure 4.9c). Here, 0.1 mg of Gm-FMNP1 shows a similar
antimicrobial efficiency to 12–15 mg of pure Gm. Our experimental results indicate that
~ 8 µg of Gm could be conjugated on 0.1 mg FMNP1 (Figure A4 and Table A1, from
Appendix 4). Furthermore, Gm- FMNP1 are able to maintain their bioactivity, even when
stored at 6 °C for 3 months.
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Figure 4.9 Antimicrobial efficiency of Gm-FMNP1 (0.1 mg/mL) with E. coli (~1.0 x 103
CFU/mL) in 1 mL solution. (a) Plate counting of (A1) E. coli alone, (A2) E. coli mixed
with FMNP1, (A3) Glu-FMNP1, (A4) EA-FMNP1, (A5) the upper-level liquid of GmFMNP1 interacting with E. coli, and (A6) the precipitate of E. coli mixed with GmFMNP1; (b) calculation the number of colony-forming unit (CFU) of all samples. (c) The
agar-diffusion assay. In the small inset image, No. 2 to No. 7 represent a 2-fold serial
dilution of Gm solutions (from 6.25 to 200 mg/mL). No. 1, No. 8, No. 9 and No. 10 refer
to the negative controls with PBS solution, EA-FMNP1 solution and Gm-FMNP1
solution stored in a fridge for 3 months, Gm- FMNP1 were freshly prepared. In all cases,
the concentration of NPs is 0.1 mg/mL.
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4.3.3 Ubiquitous capture of bacteria by Gm-FMNP2
We further developed an updated Gm modified NPs (Gm-FMNP2) for ubiquitous capture
of bacteria. We first mixed Gm-FMNP2 with bacterium E. coli. As expected, TEM image
shows clearly the attachment of NPs with bacterial cells (Figure 4.10a). We further
analyze the ability of Gm-FMNP2 for capturing Gram-positive bacterium S. aureus. As
discussed above, Gm in known to be uptaken by susceptible Gram positive bacteria such
as S. aureus strain and kill the bacterium under the regulation of membrane potential and
electrochemical gradient.54,

55

The uptake of gentamicin by S. aureus is reported

involving of ionic adherence to the cell surface and subsequently binding to a membrane
aerobic energization complex.43 Phospholiplids and teichoic acid on the surface of Grampositive bacteria were supposed to be the initial binding site for aminoglycoside
antibiotic.56, 57 Thus it is expected that our Gm modified NPs can interact with S. aureus,
and hence capture and separate bacterial cells from solution under external magnetic
field. As shown in Figure 4.10b, TEM image shows Gm-FMNP2 were found to bind on
the surface of the S. aureus. Furthermore, in the EA-FMNP2 and S. aureus group, we did
not find the interaction between the particles and bacteria.

Figure 4.10 TEM micrographs of capture of bacteria E. coli and S. aureus by GmFMNP2.
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In our study, the bacteria capture experiment in our study was done by mixing GmFMNPs with S. aureus for desired time. Although one hour incubation Gm-FMNP2 with
bacteria could reach maximum capture effect, we could also find a few bacteria even
after 10 min mixing through optical microscopy. In addition, as discussed above, the GmFMNP2 exhibit a smaller hydro-diameter and better magnetic property, due to a smaller
core with good crystalline structure and thinner silica shell. Good magnetization can
result in fast confinement of particles. Consistently, we observed the bacterium-NPs
complex (aggregation) can be confined even in 1 min under external magnetic field of 0.2
T. Using the optical microscopy, we found that the diluted S. aureus with the
concentration as low as 0.5×103 CFU/mL can be separated from the solution by the
core-shell MNPs in 1 min. Further quantitative analysis of the capture efficiency,
detection limitation and possible toxic effect of Gm-FMNP2 to S. aureus are under study.

4.4 Conclusion
In sum, we have demonstrated an efficient and fast way for ubiquitous capture, detection
and decontamination of bacteria, by conjugating antibiotic gentamicin to fluorescent
magnetic nanoparticles (FMNPs). Two different methods were developed for synthesis of
FMNPs, including a one-pot co-precipitation approach and two-step thermal
decomposition method. TEM results show that the FMNPs prepared by both methods
comprise of a Fe3O4 core and a silica (SiO2) shell. Both Gm conjugated FMNPs show a
typical superparamagnetic property. Preliminary results show that Gm-FMNP1 can
capture bacterium E. coli up 90 % of bacterium cells in a concentration of 1x 107
CFU/mL within 20 min. The detection limit was found to be as low as to a concentration
of 1 x 103 CFU/ mL through optical microscopy analysis. The antibacterial effect of GmFMNP1 to E. coli was further demonstrated by plate counting technique and the
efficiency was found 20 % enhanced. Furthermore, Gm-FMNP2 prepared by two-step
method with a better crystalline structure and magnetization, show higher capture
efficiency for capturing both gram-negative bacterium E. coli and Gm sensitive Grampositive bacterium S. aureus. By improvement of particles stability through efficient
functionalization, we estimate that the Gm-FMNPs can be a promising platform for
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simultaneous rapid capture, sensitive detection, and decontamination of bacteria for
disease control in clinic and wastewater treatment.
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CHAPTER 5
DEVELOPMENT OF LUCIFERASE CONJUGATED
GOLD NANOPARTICLES IN DETECTION OF
THROMBIN
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5.1 Introduction
Fluorescent labels have been widely used in modern biotechnology. For example, directly
labelling of biomolecules with fluorophore can locate molecules inside cell or provide
signal for immunoassay. However, biological activities are often involved in dynamic
processes, including protein interactions, ligand-receptor binding, changes of proteins and
nucleic acid conformation in response to stimulus. One signal obtained by simple
labelling is hard to provide more information. In this case, extensive using of fluorescent
labels in the form of Förster/fluorescence resonance energy transfer (FRET) provides a
powerful tool to probe those biological processes.
FRET is a process in which nonradiative energy is transferred from an excited
luminescent fluorophore (sever as a donor) to a proximal ground state fluorophore (sever
as an acceptor, typically in a few nanometers away).1 The energy transfer efficiency (E),
which is defined as the fraction of energy transfer event occurring per fluorophore donor
excitation event, is thus distance dependent, as shown in the equation (5.1) below,
E=

1

r

6

�1+�R � �
0

(5.1)

where r is the distance between two partners and R0 is the distance at which the resonance
energy transfer (RET) efficiency is 50% and represents a characteristic parameter for the
given partners. As a result, this process can be used as a “molecular ruler”, allowing one
to determine the distance between partners by measuring the changes of fluorescent
signal from the donors or acceptors.
FRET is a very sensitive and reliable technique widely used in biosensing. In particular,
detecting analytes can be achieved by using the ratio of the two different fluorescent
intensities. This could eliminate most ambiguities in the detection caused by external
assay factors such as excitation source fluctuations and sensor concentration.2, 3
In conventional FRET system, both the donor and the acceptor are fluorescent agents.
However, the process of RET can also involve bioluminescent and chemiluminescent
donor, or nonluminescent acceptors. In particular, bioluminescence resonance energy
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transfer (BRET) which is operated by biochemical energy generated by bioluminescent
protein to excite fluorophore offer additional advantages over FRET, including intrinsic
low background, less signal interference and no photobleaching issue. The reason for
those aspects is that BRET does not require external light source. In addition, BRET
possesses less harmful to biological system comparing to FRET and chemiluninescence
resonance energy transfer (CRET), as the reaction to produce light is a nature
biochemical process.
Traditionally, fluorophores such as fluorescent dyes are used in RET systems. However,
fluorescent dyes have several drawbacks such as photobleaching and high sensitivity to
environmental factors. In recent, a number of studies have incorporated nanoparticle into
the design of RET system with enhanced RET performance and flexibility in the
selection of excitation source. Nanoparticles (NPs), such as gold nanoparticles (Au NPs)
and quantum dots (QDs), possess unique optical properties and can act either a quencher
(a special acceptor) a fluorescent donor (and acceptor), respectively.
Au NPs can serve as excellent fluorescence quenchers (acceptor) for RET based assay
because of their extraordinary molar extinction coefficients and broad energy absorption
bandwidth in the visible range.4, 5 In addition, the unique chemical reactivity of gold
allows Au NPs to be a suitable platform to selectively binding of a wide range of organic
or biological fluorescent ligands for detecting small molecules and biological targets. The
most common set-up for Au NPs based RET assay is the fluorescence quenching-based
switch on/off. For example, fluorescence (or bioluminescence) of the donor is quenched
on attaching with Au NPs. The presence of analytes results in release (or extends the
usable distances) of donor from Au NPs and hence restores the fluorescence (or
bioluminescence), of which the intensity is proportional to the amount (concentration) of
analytes. In the last decades, a number of innovative approaches using Au NPs as
quencher in RET system have been developed for the detection of metal ions,6-8 small
molecules,9, 10 nucleic acids 11 and enzymes.12, 13
Bioconjugated nanoparticles have proven to be extremely convenient and invaluable tools
for biomedical applications over last decades. Apart from using as excellent drug/gene
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delivery cargoes and bio-imaging agents, bioconjugated nanoparticles have also been
used to create nanosensors of extremely sensitivity and highly specificity in analysis of a
variety of biological analytes. Among the most important biological analytes are
protease, a group of enzymes that selectively cleave peptide bonds in proteins and
polypepetides via hydrolysis.14-17 Proteases not only play a crucial role in a number of
biological processes, including hormone activation, blood coagulation and apoptosis, but
also are involved in many diseases, such as viral infection, cancer, and inflammatory
disease. The development of approaches for detecting and real time monitoring of
protease is of great interest as they can be biomarker for certain disease.17
One of important proteases is thrombin. Thrombin is a serine protease that plays a central
role in haemostasis by converting soluble fibrinogen to fibrin clot.18, 19 Thrombin has
been reported involved in variety of diseases, such as rheumatoid arthritis,20 pulmonary
fibrosis

21

and glomerulonephritis. 22 The concentration of thrombin in both blood and

urine of health bodies is almost undetectable, as it exhibits in the form of prothrombin (or
thrombin-antithrombin complex).23,

24

However, it can reach to low micromolar level

during coagulation process and early haemostatic process in plasma.23 In the urine
samples from glomerulonephritis patients, even low level of thrombin has been
generated.24 A number of strategies have thus been developed for sensing and monitoring
thrombin, including antibody based radioimmunoassay/ELISA,23 fluorophore labelled
substrate bound sensor,25-28 and recent developed nucleic acid probes based
aptamersensor.29-31 Among them, peptide substrate reporters offer a lot advantages, as
they response only to the active thrombin and thus avoid false positive from prothrombin.
In addition, fluorophore labelled peptide substrate can be further incorporated into NPs
based RET system to enhance the sensitivity and reduce assay time.
In this section, we report the development of a nanosensor based on luciferase conjugated
gold nanoparticles for sensing thrombin in both buffer and urine samples. The advantage
of using urine samples is that urine samples can be easily and repetitively obtained
avoiding problems and risks associated with blood sampling. In addition, as the presence
of thrombin activity in urine is reported to be associated with glomerulonephritis, it is
possible to provide useful information for diagnosis of diseases related to kidney.24
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5.2 Experimental section
5.2.1 Design of the pRluc-Au NPs nanosensor
In this study, the design of the nanosensor for detection of thrombin concentration is
shown in Figure 5.1. The nanosensor is composed of a conjugate of alkanethiol ligand
stabilized gold nanoparticles (Au NPs) and a recombinant protein pRluc that containing a
domain of Renilla luciferase (Rluc) and a short peptide as the sensing element. Au NPs
have been demonstrated for its strong quenching effect for emission from proximate
organic fluorophores,32 fluorescent proteins,33 QDs

34

and even bioluminescence

35

in

RET system. Thus, in this system, the initial bioluminescence generated by the pRluc is
quenched due to proximal conjugation with Au NPs. However, in the presence of
thrombin, the sensing peptide is cleavage, which result in release of Rluc from
nanoparticles and hence generate bioluminescence.

Figure 5.1 Schematic diagram of detection of thrombin via pRluc conjugated gold
nanoparticles
The details of the experiment are described below. Unless otherwise stated, chemicals
were obtained from Sigma-Aldrich. Only NANOpure water (ρ=18.2 MΩ) was used.
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5.2.2 Dihydrolipoic acid (DHLA) synthesis
DHLA was synthesized by reduction of thioctic acid (TA) according to a published
procedure.36 Briefly, NaBH4 (1.2 g) was added by small portions into an aqueous solution
of TA (6 g in 117 mL of 0.25 M sodium bicarbonate solution). The mixture was stirred
vigorously under cold bath (~ 4 °C) for 30 min. Afterwards, the mixture was acidified to
~ pH 1.0 by addition of HCl. DHLA was extracted three times from the crude product by
20 mL of toluene. The organic phase was washed by water and dried under vacuum oven.
The purified DHLA was stored at room temperature under vacuum.

5.2.3 Synthesis and functionalization of Gold Nanoparticles
Gold nanoparticles were prepared via the sodium citrate reduction of HAuCl4·3H2O as
described by Frens et. al. 37 with slight modification. In brief, one hundred millilitres of 1
mM HAuCl4·3H2O in water was heated until refluxing under stirring. Following that, 5
mL of 38.8 mM sodium citrate tribasic dehydrate with water was added quickly into the
solution under vigorously stirring. The mixture was then kept under refluxing for another
15 min. The color of the solution turned from yellow to clear, black, purple and to deep
red eventually. Afterwards, the mixture was removed from heating and cool to room
temperature. The resultant solution was then filter through 0.45-μm acetate filter to
remove large agglomerates and stored at room temperature under dark.
Citrate-stabilized gold nanoparticles were further functionalized by alkanethiols, i.e. 11mercaptoundecanoic acid (MUA) and DHLA. In following experiment, only MUA is
used in description of the procedure. Typically, a solution of 3 mL of the above citratestabilized gold nanoparticles (15 nM, pH adjusted to 10.0 by 0.5 M NaOH) was mixed
with 0.5 mL ethanol. Afterwards, a solution of 0.5 mL ethanol dissolved with MUA (10
mM) was added in the gold solution and stirred for 19 h. The mixture was then filtered
through 0.45-μm acetate filter. The MUA modified gold nanoparticles were further
purified by amicon ultral filters (Ultra-0.5 mL). Finally, the MUA modified particles
were re-suspended in 1 mL DDW (~ 60 nM).

105

5.2.4 Plasmid constructions
A recombinant protein containing Renilla luciferase (Rluc) and a short peptide sequence
as thrombin substrate was constructed as following. Firstly, Rluc gene from the plasmid
pRL-null (Promega, Inc) was cloned into the MCS site of pET 32-a (Merck Millipore
Inc.) plasmid under two restriction sites (BamH I and Xho I). Two primers were designed
for the cloning (forward: 5' AAAGGATCCAGCGGTGGTGGTGGTAGCATGAC
TTCGAAAGTTTATGATCCAG; reverse: 5' TGTGCTCGAGTTGTTCATTTTTGA
GAACTCGCTC 3'). As shown in Figure A5 (Appendix5), thrombin substrate originally
from pET 32-a plasmid is thus located at upstream (N-terminal) of Rluc gene. A trx
region from pET 32-a coding for thioredoxin protein is kept to maintain high level of
recombinant protein expression.38 The bold underline in the forward primer indicates a
six amino acid linker (SGGGGS) was inserted after Bam H I site to leave a flexible space
for proper folding of Rluc protein.
In a typical experiment, the PCR products and the plasmid were digested with relating
restriction enzyme and purified through agarose gel, respectively. The digested DNA
insert was ligated into the relating MCS site at the plasmid. The ligation product was
transformed into E. coli BL21 cells. The successful construction of the plasmid was
confirmed by DNA sequencing (Robarts Institute, Western University).

5.2.5 Protein Expression and Purification
The above bacterial cells with recombinant plasmid were grown overnight at 37 oC in 5
mL of Luria Bertani (LB) broth containing 100 μg/mL ampicillin. This culture was used
to further inoculate 500 mL of broth containing 100 μg/ml of ampicillin, and this was
grown at 37 oC. When the culture reached an OD600 of 0.375, Isopropyl β-D-1thiogalactopyranoside (IPTG) was added to 1 mM final concentration to induce the
expression of recombinant protein pRluc and the bacteria were left to grow for 4 h at
room temperature. The cells were harvested by centrifugation at 12,000 rpm for 5 min at
4 oC. The pellet was resuspended in a binding solution (BS) of 20 mM Tris/HCl, pH 7.4,
500 mM NaCl and 5 mM imidazole and sonicated on ice using 15-s bursts followed by
30-s rest for 30 cycles using a Mandel Scientific Q500 sonicator (Guelph, Canada). The
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suspension was centrifuged at 10,000 rpm at 4 oC for 30 min to collect the supernatant
from bacterial cell pellet. The protein was purified via His-trap HP columns (GE
lifescience, Inc.) by a syringe pump. The column was first equilibrated with BS. The
supernatant containing the protein was loaded on the column, and the column was
washed with 10 column volumes of the BS. The protein was eluted using BS with a
gradient of imidazole from 20 mM to 200 mM) over 10 column volumes. Five milliliters
fractions were collected. An SDS-PAGE was run to verify the fractions containing the
fusion protein, which were pooled together. Excess imidazole was removed from the
combined fractions by buffer exchange with excess amount of 10 mM Tris/HCl, pH 7.4
using an amicon Ultra centrifugal filter (ultra-15, MWCO 10 kDa, Millipore Inc). The
resultant pRluc protein solution was stored in aliquot at -20 oC. The concentration of the
protein was determined by bicinchoninic acid (BCA) protein assay (Thermo scientific
Inc).

5.2.6 Bioconjugation of Au NPs by pRluc protein
The bioconjugation was mediated 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide
(EDC). In a typical experiment, MUA or DHLa modified Au NPs (10 μL at 60 nM),
pRluc (10 μL at 0.2 mM) and EDC (10 μL at 1 mM) were mixed in 270 μL of water. The
mixture was incubated at room temperature for 2 h under gently shaking. Afterwards, 10
μL of ethanolamine was added to stop the reaction. The pRluc Au NPs were further
purified by amicon ultra-0.5 filter.

5.2.7 Characterization
Transmission electron microscopy (TEM) was used to analyze the morphology of the asmade nanoparticles. The TEM images were obtained using a Philips CM-10 microscopy
operating at 100 kv. The modification of nanoparticles by PE and QDs were verified by
using Fourier transform infrared (FTIR) spectrophotometer (Bruker FTIR-IFS 55,
Germany). UV-visible absorption spectra were recorded by UV-3600 spectrophotometer
(Shimadzu, Japan).
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5.2.8 Thrombin assay
The pRluc-Au NPs conjugate (50 μL at 1 5 mM) was mix ed with 1 0 mM Tris bu ffer
(TBS, 240 μL, pH 7.4). The assay was initiated by addition of thrombin (from human
plasma, 1000 NIH U/mg, 1 NIH unit is approximate equal to 0.3 µg in amount, 10 μL of
each stock solution), giving final concentrations ranging from 3 ng/mL to 300 µg/mL. In
a typical experiment, the reaction was incubated at room temperature for 1 h.
Bioluminescence emission spectra were collected immediately following addition of 1 μL
of CTZ (10 mg/mL in ethanol) to the digestion solution, by a QuantaMaster™ 40
Spectrofluorometer (PTI Inc., London, ON).
For detecting the thrombin in urine, a fraction of fresh urine solution from health body
(provided by Mr. GeYi Bao from St. Joseph’s Hospital) were first pretreated by
centrifugation (6000 rpm, 15 min) and filtration (0.2 µm filter). The thrombin with
different concentrations was then spiked into a solution of pretreated urine (10% in TBS).
The pRluc-Au NPs conjugate (50 μL at 15 mM) was added into this solution. After 1 h,
bioluminescence emission spectra were collected as described above.

5.3 Results and Discussion
5.3.1 Characterization of the pRluc-Au NP conjugate
In our study, citrate stabilized Au NPs with an average diameter around 13 nm (Figure
A6a, from Appendix 6) was first synthesized, followed by surface functionalized with
alkanethiol molecules (MUA and DHLA in this study). The carboxyl group presented on
the surface of nanoparticles is then used to conjugate with the purified pRluc (MW ~ 60
kDa, Figure A6b at Appendix 6) via EDC medicated carbodiimide chemistry. Figure 5.2a
shows the UV-visible spectra of unconjugated and pRluc conjugated Au NPs. The
maximum absorption wavelength (λab

max)

for both citrate capped Au NPs and DHLA

modified Au NPs are found at 520 nm as expected. Meanwhile, MUA-Au NPs exhibits a
30-nm red shif in λab

max,

which indicates the formation of a slight aggregation of the

NPs. Au NPs are favorable for chemical absorption of alkanethiol. However, the
monothiol ligands modified colloidal gold can undergo irreversible aggregation, partially
due to the desorption of thiol from NPs surface.39 In addition, in a partially formed self108

assembled monothiol layer, long methylene groups of alkanethiol ligands render the NPs
with hydrophobic character, thereby promoting their aggregation.40 However, the
disulfide group from DHLA offers higher affinity for the ligand to bind and stabilize Au
NPs, resulting in a homogenous colloidal solution. Conjugation of pRluc to MUA-Au
NPs causes a slight red shift of λab max and a broader absorption spectrum, which might be
due to the cross-link of a pRluc molecule with several Au NPs.
We further used FTIR to investigate the conjugation of pRluc with Au NPs. As shown in
Figure 5.2b, citrate capped Au NPs shows a strong –OH stretch at 3500 cm-1. After
modification with alkanethiol ligands (only MUA modified Au NPs was showed here), a
peak is found around 1700 cm-1, which is attributed to –COOH group. A new band at
1640 cm-1 is found in the pRluc-Au NPs sample, which is due to the stretch of peptide
bond –CO-NH-. Thereby, we can conclude the pRluc is successful conjugated to Au NPs.

5.3.2 Assay optimization
We first tested the feasibility of the assay for detecting thrombin. Figure 5.3 shows that
the bioluminescence is quenched while conjugating pRluc onto Au NPs. It should be note
that, the RET only occurs when two partners approach very close to each other.41 Thus,
we did not observed any quenching of bioluminescence found in a mixture of pRluc and
Au NPs, without conjugation (data not shown). Furthermore, we found the recovery of
bioluminescence while adding thrombin to pRluc-Au NPs. It is expected this recovery of
bioluminescence is related to the concentration of thrombin, as more thrombin will free
more pRluc from Au NPs surface. In order to obtain a best correlation of the
bioluminescence signal to the analyte amount, we then test the factors that may affect the
assay performance.
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Figure 5.2 (a) UV-visible spectra and (b) FTIR spectra of bare Au NPs, alkanoethiol acid
functionalized Au NPs and pRluc conjugated Au NPs
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Figure5.3 Bioluminescent spectra of pRluc-Au NPs conjugates.
We first test the alkanethiol ligands length effect. In our study, alkanethiol ligands MUA
(11 C) and DHLA (5 C) are used to control the distance between pRluc and Au NPs,
respectively. As described above, RET ratio is reverse-proportional with distance
between fluorophores.41 Thus, it is expected that the shorter linker of DHLA could have
better quenching effect and result in higher recovered BL. However, our result (Figure
5.4a) shows the recovered BL intensity from MUA (11 C) linker is 2-fold higher than that
from DHLA. Two factors may contribute to the result. The first one might be more pRluc
molecules released from NPs by thrombin in MUA modified Au NPs, as long chain of
MUA gives more freedom between NP and protein for the access of thrombin to its
substrate peptides. The other factor may be the dramatic loss of enzyme activity in the
DHLA modified Au NPs due to conformation changes. Au NPs has been reported to
cause the loss activity for enzymes absorbed to NPs surface by change their
conformation.42, 43 Despites of lower stability of MUA Au NPs, the long chain of MUA
may offer a steric barrier preventing the direct interaction between enzymes and Au NPs.
On basis of this result, we then only use MUA modified Au NPs to conjugate pRluc in
the following assay.
We then optimized the bioconjugation process. We first examined the effect of ratio of
pRluc and MUA-Au NPs to the recovery of BL, by fixing the amount of the conjugation
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reagent EDC. Figure 5.4 b shows that the best molar ratio of pRluc to MUA Au NPs is
10000:1. Then we fixed this ratio to analyze the effect of the ratio of EDC/MUA Au NPs
to the rate of recovered BL. We found that high concentration of EDC could cause the
aggregation of nanoparticles with decreasing of the recovered BL intensity. The best
molar ratio of EDC to Au NPs is found at 10000:1 (Figure 5.4 c). Thus, the optimized
molar ratio of MUA-Au NPs, pRluc and EDC is 1:10000:10000.
We further analyzed the time effect on BL recovery by thrombin digestion. As shown in
Figure 5.4d, the relative BL ratio reaches to its first peak after 30 min incubation. No
significant changes in BL ratio with the incubation time from 1 h to 4 h. The recovered
BL ratio is 20% higher by overnight incubation than that from 1 h incubation. However,
to reduce the assay time, we determine the incubation time to one hour for our assay.

Figure 5.4 The effect of (a) ligand length, (b) the molar ratio of Au NPs and pRluc, (c)
the molar ratio of Au NPs and EDC, and (d) digestion time to the relative BL ratio.
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5.3.3 Determination of thrombin concentration in both buffer and
urine samples
We then evaluated the capability of our nanosensor to measure the activity of thrombin
under our optimized condition. As shown in Figure 5.5 a, increasing of thrombin
concentration results in an increasing of the BL emission. A linear relationship between
thrombin concentration and BL relative emission intensity is found in the rage of 300
ng/mL to 300 µg/mL, which is under the range of thrombin in human blood 23. The limit
of detection (LOD) for this assay is found to be 3 ng/mL.
We then tested nanosensor for detection of thrombin in urine samples in order to test the
influence of the biological matrix to our assay performance. By spiking the different
concentration of thrombin and pRluc Au NPs in TBS with 10% urine from healthy
subject, we did not find any significant changes for the overall assay performance in term
of both detection limit and linear response, as shown in Figure 5.5b. Therefore, the results
indicate that our nanosensor could be a potential tool for clinical diagnostic of thrombin
related diseases.

Figure 5.5 Detection of thrombin by using pRluc-Au NPs nanosensor in (a) TBS buffer
and in (b) TBS buffer spiked with human urine.

113

5.4 Conclusions and Prospects
In conclusion, we describe a bioluminescence nanosensor for highly sensitive
determination of thrombin. A linear assay response is found between 300 ng/mL to 300
µg/mL with LOD of 3 ng/mL in both buffer and urine samples. The detection of
thrombin could be achieved in 15 min. The detection range is among the range of
thrombin in Glomerulo-nephritis patients. The nanosensor can thus be a promising tool
for clinical diagnostic of thrombin related diseases.
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CHAPTER 6
SUMMARY AND RECOMMENDATIONS
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6.1 Summary and Conclusion
The overall objective of this thesis is to develop advanced nanoparticles (NPs) with welltailored surface modification and/or bioconjugation for the applications in cell tracking,
and target molecule detection. Since 1990’s, development of well-defined NPs in terms
of particles size and shape has evolved into the formation of more complex nanosystems
by combining more than two components together at nanoscale, including layer-by-layer
NPs, core-shell NPs, and organic-inorganic hybrid nanostructures. In this thesis, hybrid
NPs with special and enhanced luminescent and magnetic properties have been
developed through cost-effective chemical processes. To further apply these hybrid NPs
with enhanced chemical and physical properties in bio-imaging and bio-sensors, I applied
different strategies to engineer the hybrid NPs: (1) modify the surface of the hybrid NPs
to enhance their biocompatibility for achieving in vitro bio-imaging; (2) bioconjugate the
hybrid NPs with enzyme(s) to develop BRET nanostructured sensors. The results of my
study are briefly summarized below.
Develop biocompatible luminescent hybrid NPs for cell-tracking. In Chapter 3, the
biocompatible luminescence quantum dots (QDs) have been incorporated into gelatin
nanoparticles (NPs) through two different methods, i.e. QDs-GNP1 by encapsulating
QDs with gelatin polymer and core-shell QDs-GNP2 by layer-by-layer (LBL) coating
approach, respectively. Both gelatin/QDs systems exhibit bright luminescence and good
biocompatibility. No study has been found in using LBL techniques to prepare QDs
loaded gelatin NPs. The main points are summarized below.
1. By comparing to two synthesis processes, LBL technique indicate its advantage to enhance
the photostability of QDs over the directly encapsulation method.
2. Using LBL technique, QDs-GNPs show the typical core-shell structure. The shell made of
assembled QDs is modified by a negatively charged layer to enhance the interaction with
NIH/3T3 mouse fibroblast cells 3T3.
3. Polyelectrolytes (PE) mediated LBL coating can improve the quantum yields of QDs by
nearly two folds, and the lifetime of luminescence is found three-fold longer than that of QDs
without PE modification.
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4. We demonstrated that the luminescence of QDs in multiple-layer QDs/gelatin NPs is of
unique proton resistant, which indicates it could be a suitable imaging agents in certain
environment such as cancer cells.
Development of bioconjugated magnetic fluorescent nanomaterials for bacterial capture,

detection and antibacterial applications – Chapter 4 describes preparation of antibiotic
gentamicin (Gm) conjugated fluorescent magnetic nanoparticles (FMNPs) for rapid
capture, detection and decontamination of bacteria. The NPs consist of a fluorescent
silica shell and an iron oxide magnetic core. Initially we prepared the core-shell FMNP1
through a one-pot reaction. The NPs were then conjugated with antibiotic gentamicin. We
then demonstrated the gentamicin conjugated fluorescent magnetic nanoparticles (GmFMNP1) were able to capture, detect and deactivate bacteria Escherichia coli. To
improve the stability and capture efficiency, we further developed a two-step thermal
decomposition method to produce the fluorescent magnetic core-shell nanoparticles (i.e.
FMNP2). We extensively demonstrated the gentamicin conjugated FMNP2 (GmFMNP2) were able to capture both Gram-negative bacteria E. coli andGram-positive
bacteria Staphylococcus aureus in 1 minute.
1. FMNPs consist of Fe3O4 core and silica shell was produced. The FMNPs exhibit
superparamagnetic property.
2. Gentamicin conjugated FMNPs are able to capture both E. coli and S. aureus in as fast as 1
minute.
3. By utilizing the fluorescent property of Gm-FMNPs, we are able to detect bacterial cells at a
concentration as low as of 1 x 104 CFU/mL.
4. We demonstrated 20% higher of the antibacterial efficiency of Gm-FMNPs than that of free
gentamicin.

Luciferase conjugated NPs for biosensing applications – Chapter 5 describes the
development of bioluminescence resonance energy transfer (BRET) based nanosensors
for biosensing application. A nanosensor containing a recombinant protein (pRluc) that
consists of Renillar luciferase and a short thrombin substrate peptide at its N-terminal
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was conjugated to gold nanoparticles (Au NPs) for detecting protease thrombin in both
buffer and human urine sample spiked buffer.
1. Quench of bioluminescence was found while conjugating pRluc to Au NPs.
2. Increasing of thrombin concentration results in increasing of bioluminescence
intensity due to release of the pRluc from Au NPs.
3. Thrombin concentrations are measured in both buffer and human urine sample spiked
buffer over 300 ng/mL to 300 µg/mL with proportional relationship to the recovery of
bioluminescence.
4. The limit of detection is achieved to be 3 ng/mL. The detection of thrombin could be
achieved in 15 min.

6.2 Contributions of the Research to the Current State of
Knowledge.
Historical perspective – Prerequisite for the use of inorganic colloidal nanoparticle in
biomedicine is the proper surface functionalization of such NPs, which determine their
target applications. Critical considerations for the design of such proper surface can be
summarized below:1-3
1. The surface can stabilized the NPs in solution, particularly in water as almost all
biochemical processes occur in water. In some instances, hydrophobic surface is
required to control the growth of embryonic particles and determine the size and/or
shape of NPs. However, a ligand exchange process is necessary to bring particles
water solubility.
2. The surface must offer a reduction of toxicity of NPs in some instances, for example
for in vivo applications. A comprehensive consideration of the toxicity effect includes
in vitro and in vivo cytotoxicity, cell adhesion, circulation, etc.
3. Capping layers can offer additional functional groups at the surface for further
derivatization, such as conjugation with biomolecules.
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4. A proper surface may alter the physical properties (electronic, optical, spectroscopic
and magnetic) or chemical properties of NPs, which provides the potentials to build
multifunctional nanotools.
5. The surface layers can improve the mechanical and chemical performance of the NPs,
for example protecting core against oxidation.
6. Bioconjugated surface can ultimately determine the targeted applications of such
NPs, as well as their efficiency and specificity.
Advances in surface chemistry research offer a great of opportunities in manufacturing
NPs for the use in the field of biomedicine. The overall objective of current research
projects was the design and development of NPs with proper surface for biomedical
applications. NPs were designed to meet as many of the above criteria as possible in
order to promote their target applications.
Development of biocompatible luminescent nanocomposites for bioimaging applications
– Luminescent quantum dots (QDs) offer unique optical properties and promise
significant advantages as a new class of imaging and analytical probes in biomedical
field. However, since a large portion of the QDs is obtained in organic solvents, a phase
transfer procedure is usually required before using them in biomedical applications [9].
Another key challenge in bio-imaging application of QDs is the inherent biological
toxicity of some common used QDs (e.g. CdSe QDs).4, 5 A biocompatible layer is thus
required. Although small molecules (e.g. alkanethiol acids) have been used as a simple
and effective ligand to render hydrophobic QDs water solubility,6-11 colloidal instability
and quenching of luminescent have been reported in such QDs due to easy oxidation of
core materials and acid etching in certain physiological conditions.12 Encapsulation of
biocompatible polymer layer can offer great opportunities to overcome such drawbacks,
as they can protect the core materials from oxidation, avoid the direct interaction of
between core and living cells, and render new chemical functionalities for further grafting
of biomolecules.
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The biocompatible polymer used in my study is gelatin, a nature biocompatible
biopolymer derived from collagen. Initially, we have successfully coated QDs with
gelatin polymer by direct encapsulation (QDs-GNP1). The nano-system was found with
good biocompatibility and bright luminescent. To improve photostability of QDs
encapsulated NPs, we further applied the layer-by-layer (LBL) assembly technique to
develop a new type of gelatin/QDs core/shell nanocomposites (QDs-GNP2). To our best
knowledge, this is the first time using LBL technique to develop a gelatin-QDs nanosystem.
One of the significant features of our QDs-GNP2 is the stable luminescence with unique
proton resistant property. Multiplayer coating of polyelectrolytes (PE) was found to
enhance the QDs quantum yield and lifetime in our study. It could be attributed to that
the PE matrix may minimize the nonradiative recombination on the surface of QDs and
increase confinement of charge carrier.13, 14 In addition, we show the QDs-GNP2 with
good dispersibility and extremely stable luminescence in a wide range of pH value (pH
1.0 to 9.0). It should be noted that acid etching can cause photo bleaching of CdSe QDs,8,
15

which limit the use of QDs in some important physiological environments, such as

endosomes and lysosomes inside cells and tumor cells, where the pH are in moderate
acidic range.16, 17 Therefore the pH independent photostability of our QDs-GNP2 nanosystem may offer extra advantages for use in such conditions as imaging agents.
Furthermore, gelatin nanoparticles (GNPs) have been demonstrated as an excellent
carrier in drug and gene delivery,18-20 it is thus possible that our system that combining
QDs and gelatin materials can be an all-in-one tool for simultaneously using in drug
delivery and bio-imaging applications. In addition, the negative charge of PE coating in
our QDs-GNP2 nano-system can potentially promote the adhesion of nanocomposites to
cells surface, which may lead to longer circulation time in vivo and hence enhance the
efficiency for delivery of drug.21
Multifunctional NPs for ubiquitous capture of bacteria. MNPs have been employed for
rapid capture and detection of pathogens. The effectively and selectively targeting
requires stable and mono-dispersive NPs, as well as proper functionality.
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Silica coating offers great advantages, including enhanced water solubility, low nonspecific interaction and additional functionality.22 In our study, we have tried two
approaches in preparation of fluorescent silica coated magnetic nanoparticles (FMNPs).
One-pot synthesis approach directly renders the NPs with hydrophilic property. However,
particles are easily to form aggregations and particle size distribution is found relative
boarder. The two-step approach undergoes a high temperature synthesis process, which
provides a magnetic core with good crystalline structure. The stability of the core-shell
NPs is more stable. The small hydro-diameter of the NPs prepared by two-step method is
potential to improve the capture efficiency.
Surface functionality of NPs ultimately determines the interaction of NPs with biological
species. Antibody-modified particles have found success in cell/biomolecules labelling
and targeting. However, antibodies are only specific to certain species of pathogen.23-25 In
our study, we conjugated a small antibiotic molecule gentamicin to FMNPs. The protein
nature of antibodies makes them be denatured under certain conditions, such as high
temperature, high salt concentration, extreme solution pH, solvent, etc.26 The strong
interaction of gentamicin to cell membrane from gram-negative bacteria and some
sensitive gram-positive bacteria enables ubiquitous capture of bacteria by our gentamicin
FMNPs. In addition, as gentamicin is one of the few heat-stable antibiotics that remain
active even after autoclaving, our Gm-FMNPs are potentially reusable. Furthermore, the
intrinsic antibacterial activity of gentamicin makes our Gm-FMNPs as an excellent
disinfection agent. Due to the large ratio of surface to volume property of NPs, higher
antibacterial efficiency is expected, which is in agreement with our results.
Luciferase conjugated NPs for biosensing applications. NPs are required to conjugate
with biomolecules (e.g. proteins) of interest for further biomedical applications. Proteins
can be conjugated to the surface of NPs by adsorption, covalent conjugation and binding
through bio-affinity interaction.27 However, successful conjugation of protein to NPs
should be evaluated by several factors, such as protein activity, protein amount,
orientation, and the interaction between nanoparticle and proteins. One of the most
common used approaches is covalent conjugation mediated by carbodiimide chemistry.
In our study, we have used EDC as conjugation reagent. However, we demonstrated that
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a systematic optimization is required for EDC mediated conjugation for better assay
performance, including the molar ratio of proteins, NPs and EDC, in agreement with
others’ report.28

6.3 Limitations of the Research and Suggestions for Future
Studies
Development of biocompatible luminescent nanocomposites for bioimaging applications
Despite of the versatility of LBL coating technique for enhancing the MUA-QDs
luminescent property, the QDs used in our study exhibited low quantum yield and
relative short lifetime comparing to the commercial products. The colloid stability of
MUA coated QDs is relative poor, which could be attributed the desorption of MUA
from the surface of QDs.12, 29 It is suggested that PEG derived polymer or copolymer may
be used to improve the stability.30 In addition, coating of CdSe QDs with ZnS shell was
also reported to increase the quantum yield.6 Thus, much effort is required to make QDs
with good stability and bright luminescence.
Targeting imaging requires specific interaction of luminescent NPs with certain cells. In
our study, the adhesion of nanocomposites to cell membrane is based on electrostatic
interaction and it is non-specific. It is expected that in the future work, conjugation of
biomolecules (e.g. antibody) to nanocomposites can promote the target imaging.
Additionally, as gelatin could be an excellent carrier for drug and gene deliver, it is
promising to load drugs in the nanocomposites and realize simultaneous use in imaging
and drug delivery.
Development of bioconjugated magnetic luminescent nanomaterials for bacterial
capture, detection and antibacterial applications. Initial objective of this study is to
provide an all-in-one nanotool for simultaneous capture, detection and decontamination
of bacteria. However, the detection of bacteria is our study is based on the observation of
capture bacterial cells from fluorescent microscopy. Therefore, it is difficult to get
quantitative results. In the future work, proper readout strategies may be required. Some
of the common used techniques are fluorescent labelling of bacterial cell,31, 32 MALDIMS,33 etc. In addition, the detection sensitivity can be improved through optimizing the
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conjugation conditions (For example, use of EDC mediated conjugation rather than
glutaraldehyde cross-linking to improve conjugation efficiency).
Another critical step is to test the versatility of our Gm-FMNPs in real world
applications, such as the use in clinical diagnostic and wastewater treatment. Many
challenges may occur, including matrix interference, antibiotic resistant bacterial strains,
bacterial spores, etc. It seems that a combination of other technologies such as filtration
in wastewater treatment may be required. Furthermore, magnetically capture of the
pathogen from large sample volumes into much smaller ones allows their incorporation
onto a microfluidic device platform for development of portable analytical tools.
Luciferase conjugated NPs for biosensing applications. In chapter 5, we conjugated a
recombinant luciferase to Au NPs through EDC mediated reaction. The assay sensitivity
is largely dependent on the efficiency of luciferase released from Au NPs by thrombin
cleavage. However, some of the luciferase molecules may remain conjugated on the NPs,
if the position of the amino groups involved in the conjugation located at the C-terminal
of the substrate peptide. Therefore, a proper conjugation orientation is important for
increasing the assay sensitivity. As discussed in Chapter 2, it is promising to use
expressed protein ligation strategy to produce site-specific conjugation of protein to NPs.
One example is to use intein mediated conjugation approach to enhance such assay
sensitivity.34
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Appendix 1. Quantification of QD coated onto GNs
The amount of QDs in the core-shell QDs-GNs with LBL coating was determined by
measuring the emission intensity of QDs as a function of the concentration in triplicate at
the 470 nm of excitation. The standard curve of the emission intensity of QDs as a
function of the concentration was obtained as follows.

Figure A1. Standard curve of the emission intensity of the QDs as a function of their
concentration.
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Appendix 2. pH value effects on fluorescence decay of QDs
and core-shell QDs-GNP2
Time-resolved fluorescence measurements were measured by the TM-30 Laser Strobe
timeresolved fluorometer (Photon Technology International. PTI, London, Ontario,
Canada). The average lifetime of QDs-GNP2 (a-d) and MUA-QDs (e-h) in pH at 1, 4, 7,
and 9 are shown as follows, in which the experimental data are shown as dots, and
numerical fits as lines.
Figure A2 Fluorescence decay of QDs-GNP2 (a-d) and CdSe QDs (e-h) when the pH
value of aqueous media is 1, 4, 7, and 9, respectively; the experimental data are shown as
dots, and numerical fits as lines.
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Appendix 3. XANES spectra of FMNPs

Figure A3 Fe K-edge XANES spectra of FMNPs (black line) and model compound,
Fe3O4 (red line)
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Appendix 4. Determine the concentration of gentamicin on
Gm-FMNP1.

Figure A4. UV-vis spectra of the o-phthalalehyde derived gentamicin products from
standard gentamicin solutions.
Table A1. Absorption values at 292 nm of o-phthalalehyde -derived Gm-FMNPs
UV Absorption

Sample of Gm-FMNP1 (fresh Sample of Gm-FMNP1 (sored for
sample, 0.5 mg/mL)

Absorbance

two months, 0.5 mg/mL)

2.44

2.15
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Appendix 5. Plasmid map of recombinant protein pRluc

Figure A5. Map of plasmid containing recombinat protein pRluc (Obtained by
PlasMapper web server, http://wishart.biology.ualberta.ca/PlasMapper/)
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Appendix 6. TEM image of Au NPs and SDS-PAGE of pRluc
(b)

(a)

Figure A6 (a) TEM image of Au NPs and (b) SDS-PAGE of pRluc
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